TG Therapeutics (TGTX) 10-K 7 Mar 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 01, 2014	Jun. 30, 2013
Document Information [Line Items]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'TGTX	'	'
Entity Common Stock, Shares Outstanding	'	34,373,925	'
Entity Registrant Name	'TG THERAPEUTICS, INC.	'	'
Entity Central Index Key	'0001001316	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$74,983,321

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$40,485,466	$16,455,995
Interest receivable	27,169	0
Prepaid research and development	1,742,824	1,990,759
Other current assets	47,804	29,128
Total current assets	42,303,263	18,475,882
Long-term investment securities	4,918,897	0
Equipment, net	5,718	1,164
In-process research and development	0	2,797,600
Goodwill	799,391	799,391
Other assets	85,121	0
Total assets	48,112,390	22,074,037
Current liabilities:	'	'
Notes payable, current portion	677,778	677,778
Accounts payable and accrued expenses	4,764,502	1,117,397
Accrued compensation	532,500	145,000
Current portion of deferred revenue	152,381	152,381
Interest payable	190,017	123,511
Total current liabilities	6,317,178	2,216,067
Deferred revenue, net of current portion	1,676,191	1,828,571
Notes payable, less current portion, at fair value	64,529	2,479,098
Total liabilities	8,057,898	6,523,736
Commitments and contingencies	'	'
Equity:	'	'
Preferred stock, $0.001 par value per share (10,000,000 shares authorized, 0 issued and outstanding as of December 31, 2013 and 2012)	0	0
Common stock, $0.001 par value per share (500,000,000 shares authorized, 34,336,235 and 25,820,738 shares issued, 34,294,926 and 25,807,212 shares outstanding at December 31, 2013 and 2012, respectively)	34,336	25,821
Contingently issuable shares	6	6
Additional paid-in capital	79,658,490	34,534,805
Treasury stock, at cost, 41,309 and 13,526 shares at December 31, 2013 and 2012, respectively	-234,337	-84,538
Deficit accumulated in the development stage	-39,404,003	-18,925,793
Total equity	40,054,492	15,550,301
Total liabilities and equity	$48,112,390	$22,074,037

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets [Parenthetical] (USD $)	Dec. 31, 2013	Dec. 31, 2012
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common Stock, Shares Authorized	500,000,000	500,000,000
Common stock, shares issued	34,336,235	25,820,738
Common stock, shares outstanding	34,294,926	25,807,212
Treasury stock	41,309	13,526

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended		25 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
License revenue	$152,381	$19,048	$171,429
Research and development:	'	'	'
Noncash stock expense associated with in-licensing agreement	0	16,578,000	16,875,000
Noncash compensation	1,041,519	455,809	1,497,328
Other research and development	12,621,161	3,994,182	16,645,626
Total research and development	13,662,680	21,027,991	35,017,954
General and administrative:	'	'	'
Noncash compensation	4,161,629	2,966,373	7,214,496
Other general and administrative	2,496,461	1,815,083	4,779,741
Total general and administrative	6,658,090	4,781,456	11,994,237
Impairment of in-process research and development	2,797,600	1,104,700	3,902,300
Total costs and expenses	23,118,370	26,914,147	50,914,491
Operating loss	-22,965,989	-26,895,099	-50,743,062
Other (income) expense:	'	'	'
Interest income	-30,822	-15,787	-46,609
Other income	-108,894	-272,232	-381,126
Interest expense	952,888	905,744	1,865,729
Change in fair value of notes payable	-3,300,951	-1,659,872	-4,960,823
Total other income, net	-2,487,779	-1,042,147	-3,522,829
Loss before income taxes	-20,478,210	-25,852,952	-47,220,233
Income taxes	0	330,000	330,000
Consolidated net loss	-20,478,210	-26,182,952	-47,550,233
Net loss attributable to non-controlling interest	0	-8,110,233	-8,146,230
Net loss attributable to TG Therapeutics, Inc. and Subsidiaries	($20,478,210)	($18,072,719)	($39,404,003)
Basic and diluted net loss per common share (in dollars per share)	($0.81)	($1.38)	'
Weighted average shares used in computing basic and diluted net loss per common share (in shares)	25,413,964	13,113,758	'

Consolidated_Statements_of_Equ

Consolidated Statements of Equity (USD $)	Total	Preferred Stock [Member]	Common Stock [Member]	Contingently Issuable Share [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Deficit during Development Stage [Member]	Noncontrolling Interest [Member]	Restricted Common Stock [Member]	Restricted Common Stock [Member]
										Additional Paid-in Capital [Member]
Balance at Dec. 31, 2010	'	'	'	'	'	'	'	'	'	'
Common stock issued to founders in exchange for seed capital in April 2011	$106,578	'	$2,500	'	$104,078	'	'	'	'	'
Common stock issued to founders in exchange for seed capital in April 2011 (in shares)	'	'	2,500,000	'	'	'	'	'	'	'
Stock issued at $2.25 per share in exchange for license option	297,000	'	132	'	296,868	'	'	'	'	'
Stock issued at $2.25 per share in exchange for license option (in shares)	'	'	132,000	'	'	'	'	'	'	'
Issuance of restricted stock	1,150	'	1,150	'	'	'	'	'	'	'
Issuance of restricted stock (in shares)	'	'	1,150,000	'	'	'	'	'	'	'
Effect of reverse acquisition (in shares)	'	281,250	-2,500,124	'	'	'	'	'	'	'
Effect of reverse acquisition	322,964	281	-2,501	6	277,500	'	'	47,678	'	'
Conversion of note payable to preferred stock	55,271	3	'	'	55,268	'	'	'	'	'
Conversion of note payable to preferred stock (in shares)	'	2,763	'	'	'	'	'	'	'	'
Issuance of replacement restricted preferred stock to employees	0	129	-1,150	'	1,021	'	'	'	'	'
Issuance of replacement restricted preferred stock to employees (in shares)	'	129,375	-1,150,000	'	'	'	'	'	'	'
Stock issued, net of expenses	9,655,816	'	4,930	'	9,650,886	'	'	'	'	'
Stock issued, net of expenses (in shares)	'	'	4,929,523	'	'	'	'	'	'	'
Compensation in respect of restricted stock and stock options granted to employees, directors and consultants	86,494	'	'	'	86,494	'	'	'	'	'
Net loss	-889,071	'	'	'	'	'	-853,074	-35,997	'	'
Balance at Dec. 31, 2011	9,636,202	413	5,061	6	10,472,115	'	-853,074	11,681	'	'
Balance (in shares) at Dec. 31, 2011	'	413,388	5,061,399	'	'	'	'	'	'	'
Issuance of restricted stock	0	'	5,902	'	-5,902	'	'	'	'	'
Issuance of restricted stock (in shares)	'	'	5,901,743	'	'	'	'	'	'	'
Stock issued, net of expenses	12,181,406	696	'	'	12,180,710	'	'	'	'	'
Stock issued, net of expenses (in shares)	'	695,428	'	'	'	'	'	'	'	'
Compensation in respect of restricted stock and stock options granted to employees, directors and consultants	188,509	'	'	'	188,509	'	'	'	3,233,674	3,233,674
Shares issued in subsidiary to non-controlling interest in connection with in-licensing agreement	16,578,000	'	'	'	'	'	'	16,578,000	'	'
Conversion of preferred stock to common stock in conjunction with reverse stock split	0	-1,109	9,858	'	-8,749	'	'	'	'	'
Conversion of preferred stock to common stock in conjunction with reverse stock split (in shares)	'	-1,108,816	9,857,596	'	'	'	'	'	'	'
Non-controlling interest subsidiary shares exchanged for shares in TG Therapeutics, Inc.	0	'	5,000	'	8,474,448	'	'	-8,479,448	'	'
Non-controlling interest subsidiary shares exchanged for shares in TG Therapeutics, Inc. (in shares)	'	'	5,000,000	'	'	'	'	'	'	'
Surrender of common stock for tax withholding	-84,538	'	'	'	'	-84,538	'	'	'	'
Surrender of common stock for tax withholding (in shares)	'	'	'	'	'	13,526	'	'	'	'
Net loss	-26,182,952	'	'	'	'	'	-18,072,719	-8,110,233	'	'
Balance at Dec. 31, 2012	15,550,301	0	25,821	6	34,534,805	-84,538	-18,925,793	0	'	'
Balance (in shares) at Dec. 31, 2012	'	0	25,820,738	'	'	13,526	'	'	'	'
Issuance of restricted stock	0	'	944	'	-944	'	'	'	'	'
Issuance of restricted stock (in shares)	'	'	944,464	'	'	'	'	'	'	'
Stock issued, net of expenses	37,648,280	'	6,555	'	37,641,725	'	'	'	'	'
Stock issued, net of expenses (in shares)	'	'	6,555,000	'	'	'	'	'	'	'
Compensation in respect of restricted stock and stock options granted to employees, directors and consultants	5,203,148	'	'	'	5,203,148	'	'	'	'	'
Issuance of common stock in connection with exercise of warrants	2,280,773	'	1,013	'	2,279,760	'	'	'	'	'
Issuance of common stock in connection with exercise of warrants (in shares)	'	'	1,013,009	'	'	'	'	'	'	'
Issuance of common stock in connection with cashless exercise of warrants	-1	'	3	'	-4	'	'	'	'	'
Issuance of common stock in connection with cashless exercise of warrants (in Shares)	'	'	3,024	'	'	'	'	'	'	'
Surrender of common stock for tax withholding	-149,799	'	'	'	'	-149,799	'	'	'	'
Surrender of common stock for tax withholding (in shares)	'	'	'	'	'	27,783	'	'	'	'
Net loss	-20,478,210	'	'	'	'	'	-20,478,210	'	'	'
Balance at Dec. 31, 2013	$40,054,492	$0	$34,336	$6	$79,658,490	($234,337)	($39,404,003)	$0	'	'
Balance (in shares) at Dec. 31, 2013	'	0	34,336,235	'	'	41,309	'	'	'	'

Consolidated_Statements_of_Equ1

Consolidated Statements of Equity [Parenthetical] (USD $)	12 Months Ended			12 Months Ended
	Dec. 31, 2013	Dec. 31, 2011	Dec. 31, 2011	Dec. 31, 2012
		Exchange For License Option [Member]	Common Stock [Member]	Preferred Stock [Member]
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$2,664,970	'	'	'
Fair Value Per Share Issued	'	$2.25	$2.25	'
Preferred Stock Issued	'	'	'	$20

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended		25 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES	'	'	'
Consolidated net loss	($20,478,210)	($26,182,952)	($47,550,233)
Adjustments to reconcile consolidated net loss to net cash used in operating activities:	'	'	'
Stock compensation expense	5,203,148	3,422,182	8,711,824
Noncash stock expense associated with in-licensing agreement	0	16,578,000	16,875,000
Impairment of in-process research and development	2,797,600	1,104,700	3,902,300
Depreciation	1,127	235	1,362
Amortization of premiums on investment securities, net	975	0	975
Change in fair value and accrued interest of notes payable	-2,414,569	-815,699	-3,230,268
Changes in assets and liabilities, net of effects of acquisition:	'	'	'
Decrease (increase) in other current assets	229,258	-1,932,710	-1,699,859
Increase in accrued interest receivable	-27,169	0	-27,169
Increase in other assets	-85,121	0	-85,121
Increase in accounts payable and accrued expenses	4,034,605	595,757	5,038,672
Increase in interest payable	66,506	61,571	135,174
(Decrease) increase in deferred revenue	-152,381	1,980,952	1,828,571
Net cash used in operating activities	-10,824,231	-5,187,964	-16,098,772
CASH FLOWS FROM INVESTING ACTIVITIES	'	'	'
Purchases of equipment	-5,681	-1,399	-7,080
Investment in held-to-maturity long-term securities	-4,919,871	0	-4,919,871
Cash acquired in connection with acquisition	0	0	10,386
Net cash used in investing activities	-4,925,552	-1,399	-4,916,565
CASH FLOWS FROM FINANCING ACTIVITIES	'	'	'
Proceeds from exercise of warrants	2,280,773	0	2,280,773
Payments of short-term loans	0	-200,001	-200,001
Proceeds from sale of common stock, net	37,648,280	0	47,472,962
Proceeds from sale of preferred stock, net	0	12,257,309	12,257,309
Offering costs paid	0	-75,903	-75,903
Purchase of treasury stock	-149,799	-84,538	-234,337
Net cash provided by financing activities	39,779,254	11,896,867	61,500,803
NET INCREASE IN CASH AND CASH EQUIVALENTS	24,029,471	6,707,504	40,485,466
Cash and cash equivalents at beginning of period	16,455,995	9,748,491	0
CASH AND CASH EQUIVALENTS AT END OF PERIOD	40,485,466	16,455,995	40,485,466
NONCASH TRANSACTIONS	'	'	'
Conversion of notes payable to preferred stock	0	0	55,271
Accrued financing costs	$0	$0	$61,138

ORGANIZATION_AND_SUMMARY_OF_SI

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	DESCRIPTION OF BUSINESS
	We are a biopharmaceutical company focused on the acquisition, development and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding their research and development and eventually either out-licensing or bringing the technologies to market. Currently, the Company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab), is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. We are also developing TGR-1202, an orally available PI3K delta inhibitor. We also hold the development rights to AST-726, a nasally delivered product for the treatment of Vitamin B12 deficiency.
	Exchange Transaction with TG Therapeutics, Inc. and its majority shareholders
	On December 29, 2011, the Company entered into and consummated an Exchange Transaction Agreement with Opus Point Partners, LLC (“Opus”) and TG Biologics, Inc. (formerly known as TG Therapeutics, Inc.) (“TG Bio”) (the “Agreement”). Under the Agreement, Opus exchanged (the “Exchange Transaction”) its shares of common stock in TG Bio (“TG Bio Common Stock”) for shares of Series A preferred stock in the Company (“Company Preferred Stock”). In accordance with the terms of the Agreement, 95% of the holders of common stock of TG Bio (one (1) minority shareholder of TG Bio holding in aggregate 132,000 shares of common stock of TG Bio did not participate) surrendered their TG Bio common stock. The Agreement caused the Company to issue to TG Bio’s shareholders 281,250 shares of Company Preferred Stock. Each share of Company Preferred Stock was convertible into 8.89 shares of the Common Stock provided that such conversion rights were subject to sufficient available authorized shares of Common Stock. In connection with the reverse stock split effected by the Company on April 30, 2012 (as discussed below), all shares of preferred stock issued in connection with the Agreement were converted to Common Stock. The Company Preferred Stock issued in connection with the Agreement provided the former TG Bio shareholders with direct and/or indirect ownership of approximately 95% of the Company’s outstanding Company Common Stock immediately following the consummation of the transaction.
	Since the stockholders of TG Bio received the majority of the voting shares of the Company, the merger was accounted for as a reverse acquisition whereby TG Bio was the accounting acquirer (legal acquiree) and the Company was the accounting acquiree (legal acquirer) under the acquisition method of accounting. TG Bio was incorporated in Delaware in November 2010, but did not commence operations until April 2011.
	The filings with the Securities and Exchange Commission (the “SEC”) include the historical financial results of TG Bio and will hereafter collectively be referred to as the Company.
	On April 30, 2012, the Company filed a Certificate of Amendment to its Certificate of Incorporation to change its name from Manhattan Pharmaceuticals, Inc. (“Manhattan”) to TG Therapeutics, Inc. In conjunction with this change, the subsidiary formerly named TG Therapeutics, Inc. filed a Certificate of Amendment changing its name to TG Biologics, Inc.
	LIQUIDITY AND CAPITAL RESOURCES
	We have incurred operating losses since our inception, and expect to continue to incur operating losses for the foreseeable future and may never become profitable. As of December 31, 2013, we have an accumulated deficit of $39,404,003.
	Our primary source of cash has been proceeds from the sale of equity securities, the upfront payment from our Sublicense Agreement with Ildong Pharmaceutical Co. Ltd. (“Ildong”), and warrant exercises. We have not yet commercialized any of our drug candidates and cannot be sure if we will ever be able to do so. Even if we commercialize one or more of our drug candidates, we may not become profitable. Our ability to achieve profitability depends on a number of factors, including our ability to obtain regulatory approval for our drug candidates, successfully complete any post-approval regulatory obligations and successfully commercialize our drug candidates alone or in partnership. We may continue to incur substantial operating losses even if we begin to generate revenues from our drug candidates.
	As of December 31, 2013, we had $45,431,532 in cash, cash equivalents, investment securities, and interest receivable. We currently anticipate that our cash and cash equivalents to be sufficient to fund our anticipated operating cash requirements for approximately 24 months from December 31, 2013. The actual amount of cash that we will need to operate is subject to many factors, including, but not limited to, the timing, design and conduct of clinical trials for our drug candidates. We are dependent upon significant future financing to provide the cash necessary to execute our current operations, including the commercialization of any of our drug candidates.
	Our common stock is quoted on the NASDAQ Capital Market and trades under the symbol “TGTX.”
	REVERSE STOCK SPLIT
	On April 30, 2012, the Company effected a reverse split of its Common Stock at a ratio of 56.25 for 1, pursuant to a previously obtained stockholder authorization. All share amounts and per share prices in this Annual Report on Form 10-K have been retroactively adjusted to reflect the effect of our reverse stock split, on a fifty-six and one quarter (56.25) for one (1) basis, unless otherwise indicated.  The exercise price for all stock options and warrants and the conversion price for convertible securities in the accompanying consolidated financial statements have been adjusted to reflect the reverse stock split by multiplying the original exercise or conversion price by fifty-six and one quarter (56.25).
	RECENTLY ISSUED ACCOUNTING STANDARDS
	In July 2013, the Financial Accounting Standards Board, or FASB, issued a new accounting standard which will require the presentation of certain unrecognized tax benefits as reductions to deferred tax assets rather than as liabilities in the consolidated balance sheets when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The new standard requires adoption on a prospective basis in the first quarter of 2015; however, early adoption is permitted. The Company does not anticipate that this adoption will have a significant impact on its financial position, results of operations, or cash flows.
	Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to the consolidated financial statements of the Company.
	BASIS OF PRESENTATION
	The Company has generated limited revenue from its operations and, accordingly, the financial statements have been prepared in accordance with the provisions of accounting and reporting for Development Stage Enterprises.
	USE OF ESTIMATES
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the applicable reporting period. Actual results could differ from those estimates. Such differences could be material to the financial statements.
	CASH AND CASH EQUIVALENTS
	We treat liquid investments with original maturities of less than three months when purchased as cash and cash equivalents.
	INVESTMENT SECURITIES
	Investment securities at December 31, 2013 consist of long-term government securities. We classify our long-term debt securities as held-to-maturity. Held-to-maturity securities are those securities in which we have the ability and intent to hold the security until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized or accreted over the life of the related held-to-maturity security as an adjustment to yield using the effective interest method.
	A decline in the market value of any investment security below cost, that is deemed to be other than temporary, results in a reduction in the carrying amount to fair value. The impairment is charged to operations and a new cost basis for the security is established. Other-than-temporary impairment charges are included in interest and other income, net. Unrealized gains, if determined to be temporary, are included in accumulated other comprehensive income in stockholders’ equity. Dividend and interest income are recognized when earned.
	REVENUE RECOGNITION
	We recognize license revenue in accordance with the revenue recognition guidance of the FASB Accounting Standards Codification, or Codification. We analyze each element of our licensing agreement to determine the appropriate revenue recognition. The terms of the license agreement may include payments to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. We recognize revenue from upfront payments over the period of significant involvement under the related agreements unless the fee is in exchange for products delivered or services rendered that represent the culmination of a separate earnings process and no further performance obligation exists under the contract. We recognize milestone payments as revenue upon the achievement of specified milestones only if (1) the milestone payment is non-refundable, (2) substantive effort is involved in achieving the milestone, (3) the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone, and (4) the milestone is at risk for both parties. If any of these conditions are not met, we defer the milestone payment and recognize it as revenue over the estimated period of performance under the contract.
	RESEARCH AND DEVELOPMENT COSTS
	Generally, research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are delivered or the related services are performed, subject to an assessment of recoverability. We make estimates of costs incurred in relation to external clinical research organizations, or CROs, and clinical site costs. We analyze the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and estimates must be made and used in determining the accrued balance and expense in any accounting period. We review and accrue CRO expenses and clinical trial study expenses based on work performed and rely upon estimates of those costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under these contracts may be uneven, and depend on factors such as the achievement of certain events, the successful recruitment of patients, the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the recording of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical study or trial contract.
	IN-PROCESS RESEARCH AND DEVELOPMENT
	All acquired research and development projects are recorded at their fair value as of the date acquisition. The fair values are assessed as of the balance sheet date to ascertain if there has been any impairment of the recorded value. If there is an impairment, the asset is written down to its current fair value by the recording of an expense. Impairment is tested on an annual basis or sooner, if there is an indication of impairment, and consists of a comparison of the fair value of the in-process research and development with its carrying amount.
	INCOME TAXES
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. If the likelihood of realizing the deferred tax assets or liability is less than “more likely than not,” a valuation allowance is then created.
	We, and our subsidiaries, file income tax returns in the U.S. Federal jurisdiction and in various states. We have tax net operating loss carryforwards that are subject to examination for a number of years beyond the year in which they were generated for tax purposes. Since a portion of these net operating loss carryforwards may be utilized in the future, many of these net operating loss carryforwards will remain subject to examination.
	We recognize interest and penalties related to uncertain income tax positions in income tax expense.
	STOCK - BASED COMPENSATION
	We recognize all share-based payments to employees and to non-employee directors as compensation for service as compensation expense in the consolidated financial statements based on the fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
	For share-based payments to consultants and other third-parties, compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date. The awards to consultants and other third-parties are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent reporting date.
	BASIC AND DILUTED NET (LOSS) INCOME PER COMMON SHARE
	Basic net income (loss) per common share is calculated by dividing net income (loss) applicable to common shares by the weighted-average number of common shares outstanding for the period. Diluted net loss per common share is the same as basic net income (loss) per common share, since potentially dilutive securities from stock options, stock warrants and convertible preferred stock would have an antidilutive effect either because the Company incurred a net loss during the period presented or because such potentially dilutive securities were out of the money and the Company realized net income during the period presented. The amounts of potentially dilutive securities excluded from the calculation were 10,618,584 and 10,746,837 at December 31, 2013 and 2012, respectively. During the years ended December 31, 2013 and 2012 the Company incurred a net loss, therefore, all of the dilutive securities are excluded from the computation of diluted earnings per share.
	LONG-LIVED ASSETS AND GOODWILL
	Long-lived assets are reviewed for an impairment loss when circumstances indicate that the carrying value of long-lived tangible and intangible assets with finite lives may not be recoverable. Management’s policy in determining whether an impairment indicator exists, a triggering event, comprises measurable operating performance criteria as well as qualitative measures. If an analysis is necessitated by the occurrence of a triggering event, we make certain assumptions in determining the impairment amount. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized.
	Goodwill is reviewed for impairment annually, or when events arise that could indicate that an impairment exists. We test for goodwill impairment using a two-step process. The first step compares the fair value of the reporting unit with the unit's carrying value, including goodwill. When the carrying value of the reporting unit is greater than fair value, the unit’s goodwill may be impaired, and the second step must be completed to measure the amount of the goodwill impairment charge, if any. In the second step, the implied fair value of the reporting unit’s goodwill is compared with the carrying amount of the unit’s goodwill. If the carrying amount is greater than the implied fair value, the carrying value of the goodwill must be written down to its implied fair value. We will continue to perform impairment tests annually, at December 31, and whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable.

CASH_AND_CASH_EQUIVALENTS

CASH AND CASH EQUIVALENTS	12 Months Ended
	Dec. 31, 2013
Cash and Cash Equivalents [Abstract]	'
Cash and Cash Equivalents Disclosure [Text Block]	'
	NOTE 2 – CASH AND CASH EQUIVALENTS
		December 31, 2013		December 31, 2012
	Money market funds	$	554,069	$	500,007
	Checking and bank deposits		39,931,397		15,955,988
	Total	$	40,485,466	$	16,455,995

INVESTMENT_SECURITIES

INVESTMENT SECURITIES	12 Months Ended
	Dec. 31, 2013
Investments, Debt and Equity Securities [Abstract]	'
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	'
	NOTE 3 – INVESTMENT SECURITIES
	We record our investments as either held-to-maturity or available-for-sale. Held-to-maturity investments are recorded at amortized cost.
	We were not invested in investment securities at December 31, 2012. The following tables summarize our investment securities at December 31, 2013:
		December 31, 2013
		Amortized cost,		Gross		Gross		Estimated
		as adjusted		unrealized		unrealized		fair value
				holding gains		holding losses
	Long-term investments:
	Obligations of domestic governmental agencies	$	4,918,897	$	—	$	650	$	4,918,247
	(maturing between January 2015 and April 2015) (held-to-maturity)
	Total long-term investment securities	$	4,918,897	$	—	$	650	$	4,918,247

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	NOTE 4 – FAIR VALUE MEASUREMENTS
	We measure certain financial assets and liabilities at fair value on a recurring basis in the financial statements. The fair value hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:
		⋅	Level 1 – quoted prices in active markets for identical assets and liabilities;
		⋅	Level 2 – inputs other than Level 1 quoted prices that are directly or indirectly observable; and
		⋅	Level 3 – unobservable inputs that are not corroborated by market data.
	As of December 31, 2013 and 2012, the fair values of cash and cash equivalents, and notes and interest payable, current portion approximate their carrying value.
	Upon the merger between Manhattan and Ariston Pharmaceuticals, Inc. (“Ariston”) in March 2010, Ariston issued $15,452,793 of five-year 5% notes payable (the “5% Notes”) in satisfaction of several note payable issuances.  The 5% Notes and accrued and unpaid interest thereon are convertible at the option of the holder into Common Stock at the conversion price of $1,125 per share.  Ariston agreed to make quarterly payments on the 5% Notes equal to 50% of the net product cash flow received from the exploitation or commercialization of Ariston’s product candidates, AST-726 and AST-915.  The Company has no obligations under the 5% Notes aside from a) 50% of the net product cash flows from Ariston’s product candidates, if any, payable to noteholders; and b) the conversion feature, discussed above.
	In connection with the Exchange Transaction in December 2011, the Company performed a valuation of the assets and liabilities of Manhattan immediately prior to the transaction. The cumulative liability including accrued and unpaid interest of these notes was approximately $16,876,000 immediately prior to the Exchange Transaction, and $18,614,000 and $17,727,000 at December 31, 2013 and 2012, respectively. As these notes payable are tied directly to net product cash flows derived from the preexisting products of the Company, this note and accrued interest was recorded at fair value of $3,287,700 as of the date of the Exchange Transaction. No payments have been made on these notes as of December 31, 2013.
	We elected the fair value option for valuing the 5% Notes upon the completion of the reverse merger with TG Bio, as discussed above. The Company elected the fair value option in order to reflect in our financial statements the assumptions that market participants use in evaluating these financial instruments.
	For the year ended December 31, 2012, the valuation method used to estimate the 5% Notes’ fair value was a discounted cash flow model, where the expected cash flows of AST-726 and AST-915 were discounted to the present using a yield that incorporated compensation for the probability of success in clinical development and marketing, among other factors. The discount rate used in this discounted cash flow model approximated 20% at December 31, 2012. As of December 31, 2013, as a result of expiring intellectual property rights and other factors as discussed below in Nonrecurring Fair Value Measurements, it was determined that net product cash flows from AST-726 were unlikely. As the Company has no other obligations under the 5% Notes aside from the net product cash flows and the conversion feature, the conversion feature was used to estimate the 5% Notes’ fair value as of December 31, 2013. The assumptions, assessments and projections of future revenues are subject to uncertainties, are difficult to predict and require significant judgment. The use of different assumptions, applying different judgment to inherently subjective matters and changes in future market conditions could result in significantly different estimates of fair value and the differences could be material to our consolidated financial statements.
	The Company’s financial liabilities measured at fair value on a recurring basis as of December 31, 2013 and 2012 were as follows:
				Financial liabilities at fair value
				as of December 31, 2013
				Level 1			Level 2			Level 3			Total
	5% Notes			$	—		$	—		$	64,529		$	64,529
	Totals			$	—		$	—		$	64,529		$	64,529
			Financial liabilities at fair value
			as of December 31, 2012
			Level 1			Level 2			Level 3			Total
	5% Notes		$	—		$	—		$	2,479,098		$	2,479,098
	Totals		$	—		$	—		$	2,479,098		$	2,479,098
	The Level 3 amounts above represent the fair value of the 5% Notes and related accrued interest.
	The following table summarizes the changes in Level 3 instruments for the years ended December 31, 2012 and 2013:
	Balance at January 1, 2012		$	3,294,797
	Interest accrued on face value of 5% Notes			844,173
	Change in fair value of Level 3 liabilities			-1,659,872
	Balance at December 31, 2012			2,479,098
	Interest accrued on face value of 5% Notes			886,382
	Change in fair value of Level 3 liabilities			-3,300,951
	Balance at December 31, 2013		$	64,529
	The change in the fair value of the Level 3 liabilities is reported in other (income) expense in the accompanying consolidated statements of operations.
	Nonrecurring Fair Value Measurements
	The Company’s assets measured at fair value on a nonrecurring basis as of December 31, 2013 and 2012 were as follows:
			Fair value measurements										Total impairment charge  for the year ended
			as of December 31, 2013
			Level 1			Level 2			Level 3				December 31, 2013
	Assets:
	In-process research and development		$	—		$	—		$	—		$	-2,797,600
	Total		$	—		$	—		$	—		$	-2,797,600
			Fair value measurements										Total impairment charge for the year ended
			as of December 31, 2012
			Level 1			Level 2			Level 3				December 31, 2012
	Assets:
	In-process research and development		$	—		$	—		$	2,797,600		$	-1,104,700
	Total		$	—		$	—		$	2,797,600		$	-1,104,700
	As of December 31, 2013, as a result of expiring intellectual property rights, uncertain regulatory pathways, and market changes affecting the commercial potential for the Ariston in-process research and development asset (AST-726), the Company determined that the asset's carrying value was no longer recoverable. Accordingly, during the year ended December 31, 2013, we recorded a non-cash impairment charge of  $2,797,600, which was recorded as impairment of in-process research and development in our consolidated statements of operations. The fair value of this asset was determined to be zero primarily as a result of the expiring intellectual property rights surrounding the asset. This fair value measurement technique is based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy.
	As of December 31, 2012, as a result of market changes affecting the commercial potential for the Ariston in-process research and development assets (AST-726 and AST-915), the Company determined that the asset's carrying value was no longer fully recoverable. Accordingly, during the year ended December 31, 2012, we recorded a non-cash impairment charge of  $1,104,700, which was recorded as impairment of in-process research and development in our consolidated statements of operations. The fair value of this asset was determined using a discounted cash flow model, where the expected cash flows of the Ariston assets are discounted to the present using a yield that incorporates compensation for the probability of success in clinical development and marketing, among other factors. This fair value measurement technique is based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. Also contributing to the impairment charge recorded during the period ended December 31, 2012 was the Company’s decision during 2012 to discontinue future development activities for AST-915, following the analysis from a Phase I dose escalation trial, in which AST-915 failed to meet its primary efficacy endpoint.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Shareholders Equity and Share-based Payments [Text Block]	'
	NOTE 5 – STOCKHOLDERS’ EQUITY
	Preferred Stock
	Our amended and restated certificate of incorporation authorizes the issuance of up to 10,000,000 shares of preferred stock, $0.001 par value, with rights senior to those of our common stock, issuable in one or more series. Upon issuance, the Company can determine the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock.
	Common Stock
	Our amended and restated certificate of incorporation authorizes the issuance of up to 500,000,000 shares of $0.001 par value common stock.
	On December 30, 2011, we completed the first closing of the private placement of our securities, issuing 4,929,523 shares of Common Stock at a price per share of $2.25 for total gross proceeds, before placement commissions and expenses, of $11,091,425 (the “2011 Equity PIPE”). Investors also received warrants to purchase 1,232,381 shares of Common Stock. The warrants have an exercise price of $2.25 per share and are exercisable for five years.
	In 2012, we completed two additional closings of the 2011 Equity PIPE. These closings were held on January 31, 2012, and February 24, 2012. In these closings, the Company issued 695,428 shares of our Company Preferred Stock at a price per share of $20.00 for total gross proceeds, before placement commissions and expenses, of $13,908,560. Each share of Company Preferred Stock was convertible into 8.89 shares of Common Stock; provided that such conversion rights were subject to sufficient available authorized shares of Common Stock. In connection with the reverse stock split effected by the Company on April 30, 2012, all shares of Preferred Stock issued in the 2011 Equity PIPE were converted to Common Stock. Investors also received warrants to purchase 1,545,396 shares of Common Stock. The warrants have an exercise price of $2.25 per share and are exercisable for five years. The shares of Company Preferred Stock and warrants sold in these closings were offered and sold to accredited investors, including members of management, without registration under the Securities Act, or state securities laws, in reliance on the exemptions provided by Section 4(2) of the Securities Act, and Regulation D promulgated thereunder and in reliance on similar exemptions under applicable state laws. Accordingly, the securities issued in the offering have not been registered under the Securities Act, and until so registered, these securities may not be offered or sold in the United States absent registration or availability of an applicable exemption from registration.
	On July 18, 2013, we announced the pricing of an underwritten public offering of 5,700,000 shares of our Common Stock at a price of $6.15 per share for gross proceeds of approximately $35 million. We also granted to the underwriters a 30-day option to acquire an additional 855,000 shares to cover overallotments in connection with the offering. Total net proceeds from this offering, including the overallotment, were approximately $37.6 million, net of underwriting discounts and offering expenses of approximately $2.7 million. The shares were sold under a shelf registration statement on Form S-3 (File No. 333-189015) that was previously filed and declared effective by the SEC on June 17, 2013.
	We currently have one shelf registration statement on Form S-3 filed and declared effective by the SEC (File No. 333-189015). Subsequent to the July 2013 offering, this shelf registration statement provides for the offering of up to approximately $135 million of common stock. We may offer the securities under our shelf registration statement from time to time in response to market conditions or other circumstances if we believe such a plan of financing is in the best interests of our stockholders. We believe that this shelf registration statement provides us with the flexibility to raise additional capital to finance our operations as needed.
	Treasury Stock
	As of December 31, 2013, 41,309 shares of common stock are being held by the Company in Treasury, at a cost of approximately $234,000, representing the fair market value on the date the shares were surrendered to the Company to satisfy employee tax obligations.
	Equity Incentive Plans
	We have in effect the following stock option and incentive plans.
	a. The Company has shareholder-approved incentive stock option plans for employees under which it has granted non-qualified and incentive stock options, which provided for the granting of options to purchase up to 5,333 shares of the Company’s common stock. The options have a maximum term of 10 years and vest over a period determined by the Company’s Board of Directors. At December 31, 2013, options to purchase 591 shares were outstanding, 10 shares of common stock were issued and there were no shares reserved for future grants under the Plan.
	b. In May 2012, the Company established the TG Therapeutics, Inc. Amended and Restated 2012 Incentive Plan (“2012 Incentive Plan”). Under the 2012 Incentive Plan, the compensation committee of the Company’s board of directors is authorized to grant stock-based awards to directors, consultants, employees and officers. The 2012 Incentive Plan authorizes grants to purchase up to 6,000,000 shares of authorized but unissued common stock. As of December 31, 2013, options to purchase 46,000 shares were outstanding and up to an additional 1,107,793 shares may be issued under the 2012 Incentive Plan.
	Stock Options
	The following table summarizes stock option activity for the years ended December 31, 2013 and 2012:
		Number		Weighted-			Weighted-		Aggregate Intrinsic
		of shares		average			average		Value
				exercise price			Contractual
							Term
							(in years)
	Outstanding at January 1, 2012	3,379		$	1,315.62
	Granted	46,000			4.4
	Exercised	—			—
	Forfeited	-2,475			720.45
	Expired	—			—
	Outstanding at December 31, 2012	46,904			61.08		9.44		$	—
	Granted	—			—
	Exercised	—			—
	Forfeited	-313			2,249.85
	Expired	—			—
	Outstanding at December 31, 2013	46,591		$	46.37		8.5		$	—
	Vested and expected to vest at December 31, 2013	9,591		$	208.3		8.16		$	—
	Exercisable at December 31, 2013	9,591		$	208.3		8.16		$	—
	As of December 31, 2013, there is no unrecognized compensation cost related to unvested time-based option awards. This amount does not include, as of December 31, 2013, 37,000 non-employee options outstanding which are milestone-based and vest upon certain corporate milestones. Stock-based compensation will be measured and recorded if and when a milestone occurs.
	Restricted Stock- Preferred
	Certain employees had been awarded restricted preferred stock. The restricted stock vesting consisted of milestone and time-based vesting. The following table summarizes restricted share activity for the years ended December 31, 2013 and 2012:
		Number of Shares		Weighted
		Restricted Series		Average
		A Preferred		Grant Date
		Stock(1)		Fair Value
	Outstanding at January 1, 2012	129,375		$	20
	Granted	—			—
	Vested	—			—
	Forfeited	—			—
	Conversion to restricted common stock	-129,375			20
	Outstanding at December 31, 2012	—			—
	Granted	—			—
	Vested	—			—
	Forfeited	—			—
	Outstanding at December 31, 2013	—		$	—
	(1)  The restricted preferred stock listed in the table above was granted in connection with the Exchange Transaction to certain executives. Each share of preferred stock was convertible into 8.89 shares of the Company’s Common Stock. In conjunction with the reverse split effected on April 30, 2012 (as discussed in Note 1), all outstanding restricted Preferred Stock automatically converted to 1,150,000 shares of restricted Common Stock as of that date.
	Restricted Stock- Common
	Certain employees, directors and consultants have been awarded restricted Company Common Stock. The restricted stock vesting consists of milestone and time-based vesting. The following table summarizes restricted share activity for the years ended December 31, 2013 and 2012:
		Number of Shares		Weighted
				Average
				Grant Date
				Fair Value
	Outstanding at January 1, 2012	—		$	—
	Converted preferred stock	1,150,000			2.25
	Granted	5,901,743			4.77
	Vested	-437,500			2.25
Forfeited	—			—
Outstanding at December 31, 2012	6,614,243			4.49
Granted	944,464			4.13
Vested	-523,750			2.48
Forfeited	—			—
Outstanding at December 31, 2013	7,034,957		$	4.6
Total expense associated with restricted stock grants was $5,146,743 and $3,422,182 during the years ended December 31, 2013 and 2012, respectively. As of December 31, 2013, there was approximately $7,977,072 of total unrecognized compensation cost related to unvested time based restricted stock, which is expected to be recognized over a weighted-average period of 1.9 years. This amount does not include, as of December 31, 2013, 1,800,960 shares of restricted stock outstanding which are milestone-based and vest upon certain corporate milestones; and 2,556,375 shares of restricted stock outstanding issued to non-employees (see Note 10 – Related Party Transactions for additional information). Milestone based non-cash compensation expense will be measured and recorded if and when a milestone occurs.
Warrants
The following table summarizes warrant activity for the years ended December 31, 2013 and 2012:
	Warrants		Weighted-			Aggregate
			average			Intrinsic
			exercise price			Value
Outstanding at January 1, 2012	1,625,911			5.27		$	—
Issued	5,156,599			1.21
Exercised	—			—
Expired	-1,503			2,739.75
Outstanding at December 31, 2012	6,781,007			1.58		$	14,563,539
Issued	—			—
Exercised	-1,018,068			2.25
Expired	-43,992			16.26
Outstanding at December 31, 2013	5,718,947		$	1.34		$	14,809,030
As discussed above, as part of the 2011 Equity PIPE, we issued warrants to purchase up to 2,777,962 shares of our common stock at an exercise price of $2.25 per warrant share, 757,096 of which have been exercised as of December 31, 2013. In addition, we issued to the placement agent in the transaction warrants to purchase up to 1,111,111 shares of our common stock at an exercise price of $2.48 per warrant share, 6,533 of which have been exercised as of December 31, 2013.
In connection with the Securities Exchange Agreement between the Company and LFB Group as discussed in Note 8 – License Agreements, we issued LFB Group a warrant to purchase an aggregate of 2,500,000 shares of Company Common Stock at a purchase price of $0.001 per share.
Stock-Based Compensation
The fair value of stock options granted is estimated at the date of grant using the Black-Scholes pricing model. The expected term of options granted is derived from historical data and the expected vesting period. Expected volatility is based on the historical volatility of our common stock. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. We have assumed no expected dividend yield, as dividends have never been paid to stock or option holders and will not be paid for the foreseeable future. The Company did not grant any stock options during the year-ended December 31, 2013.
The following table summarizes stock-based compensation expense information about stock options and restricted stock for the years ended December 31, 2013 and 2012:
	2013			2012
Stock-based compensation expense associated with restricted stock	$	5,146,743		$	3,422,182
Stock-based compensation expense associated with option grants		56,405			—
	$	5,203,148		$	3,422,182
Non-controlling Interest
On November 9, 2012, LFB Group exercised their right to exchange their TG Bio common stock for Company Common Stock. The Company and LFB Group entered into a Securities Exchange Agreement pursuant to which, LFB Group agreed to exchange its 7,500,000 shares of the common stock of TG Bio, for 5,000,000 shares of Company Common Stock, and a warrant to purchase an aggregate of 2,500,000 shares of Company Common Stock at a purchase price of $0.001 per share. Refer to Note 8 – License Agreements for further information.
Accordingly, in connection with the aforementioned Securities Exchange Agreement, TG Bio became a wholly owned subsidiary of the Company. Prior to the execution of the Securities Exchange Agreement LFB Group owned approximately 42.9% of TG Bio. The non-controlling interest in subsidiary balance was approximately $8,479,000 immediately prior to LFB Group exercising their option, which was transferred to equity in connection with the transaction.

NOTES_PAYABLE

NOTES PAYABLE	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	NOTE 6 – NOTES PAYABLE
	The following is a summary of notes payable:
		December 31, 2013						December 31, 2012
		Current		Non-current		Total		Current		Non-current		Total
		portion, net		portion,				portion, net		portion,
				net						net
	Convertible 5% Notes Payable	$	-	$	64,529	$	64,529	$	-	$	2,479,098	$	2,479,098
	ICON Convertible Note		677,778		-		677,778		677,778		-		677,778
	Totals	$	677,778	$	64,529	$	742,307	$	677,778	$	2,479,098	$	3,156,876
	We assumed the preceding notes payable as the result of the Exchange Transaction between the Company and TG Therapeutics, Inc. Accordingly, a valuation using the guidance in the accounting literature for business combinations (ASC 805) was performed and these notes have been presented at their fair value on the date of the transaction.
	Convertible 5% Notes Payable
	On March 8, 2010, Manhattan entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among the Company, Ariston and Ariston Merger Corp., a Delaware corporation and wholly-owned subsidiary of the Company (the "Merger Sub").  Pursuant to the terms and conditions set forth in the Merger Agreement, on March 8, 2010, the Merger Sub merged with and into Ariston (the "Merger"), with Ariston being the surviving corporation of the Merger.  As a result of the Merger, Ariston became a wholly-owned subsidiary of Manhattan.
	The 5% Notes and accrued and unpaid interest thereon are convertible at the option of the holder into Common Stock at the conversion price of $1,125 per share.  Ariston agreed to make quarterly payments on the 5% Notes equal to 50% of the net product cash flow received from the exploitation or commercialization of Ariston’s product candidates, AST-726 and AST-915.  The Company has no obligations under the 5% Notes aside from a) 50% of the net product cash flows from Ariston’s product candidates, if any, payable to noteholders; and b) the conversion feature, discussed above. Interest accrues monthly, is added to principal on an annual basis, every March 8, and is payable at maturity, which is March 8, 2015.
	In connection with the Exchange Transaction in December 2011, the Company performed a valuation of the assets and liabilities of Manhattan immediately prior to the transaction. The cumulative liability including accrued and unpaid interest of these notes was approximately $16,876,000 immediately prior to the Exchange Transaction, and $18,614,000 and $17,727,000 at December 31, 2013 and 2012, respectively. As these notes payable are tied directly to net product cash flows derived from the preexisting products of the Company, this note and accrued interest was recorded at fair value of $3,287,700 as of the date of the Exchange Transaction. No payments have been made on these notes as of December 31, 2013. See Note 4 for further details.
	ICON Convertible Note Payable
	In connection with the merger with Ariston as discussed above, Ariston satisfied an account payable of $1,275,188 to ICON Clinical Research Limited (“ICON”) through the payment of $275,188 in cash and the issuance of a three-year 5% note payable (the “ICON Note”).  The principal was to be repaid in 36 monthly installments of $27,778 commencing in April 2010.  Interest was payable monthly in arrears.   On March 1, 2011 Ariston entered into an amended and restated convertible promissory note (the “Amended ICON Note”) with ICON. The principal terms of the Amended ICON Note are that monthly payments of principal and interest will be waived for the thirteen month period ended December 31, 2011 (the “Waiver Period”) in exchange for a single payment of $100,000 on March 31, 2011, an increase in the interest on the Amended ICON Note from 5% to 8% per annum during the Waiver Period and a balloon payment on January 31, 2012. The Amended ICON Note is convertible at the option of the holder into the Company’s common stock at the conversion price of $562.50 per share. During the year ended December 31, 2013, the Company recorded $66,506 of interest expense on the Amended ICON Note. As of December 31, 2013 and 2012, the principal amount of the Amended ICON Note was $677,778, of which the entire balance has been classified as current and is reflected as notes payable, current portion, net in the accompanying consolidated balance sheets. Interest payable on the Amended ICON Note was $190,017 and $123,511 as of December 31, 2013 and 2012, respectively, and is reflected as interest payable in the accompanying consolidated balance sheets. As of December 31, 2013, this note was in default as the Company did not make the balloon payment due on January 31, 2012, or any subsequent payments. In January 2014, the Company entered into a settlement and release agreement with ICON related to this note, whereby the Company paid  $772,369 in full settlement of the principal and interest due on this note.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	NOTE 7 – INCOME TAXES
	We account for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. In determining the need for a valuation allowance, management reviews both positive and negative evidence, including current and historical results of operations, future income projections and the overall prospects of our business. Based upon management's assessment of all available evidence, we believe that it is more-likely-than-not that the deferred tax assets will not be realizable, and therefore, a valuation allowance has been established. The valuation allowance for deferred tax assets was approximately $46,283,000 and $36,271,000 as of December 31, 2013 and 2012, respectively.
	As of December 31, 2013, we have U.S. net operating loss carryforwards (“NOLs”) of approximately $84,182,000. For income tax purposes, these NOLs will expire in various amounts through 2033. The Tax Reform Act of 1986 contains provisions which limit the ability to utilize net operating loss carryforwards in the case of certain events including significant changes in ownership interests. The Exchange Transaction with TG Bio may have resulted in a “change in ownership” as defined by IRC Section 382 of the Internal Revenue Code of 1986, as amended. Accordingly, a substantial portion of the Company’s NOLs above may be subject to annual limitations in reducing any future year’s taxable income.
	The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2013 and 2012 are presented below.
		2013		2012
	Deferred tax assets (liabilities):
	Net operating loss carryforwards	$	32,399,879	$	32,190,080
	Research and development credit		2,266,167		1,882,238
	Noncash compensation		10,971,912		3,051,920
	Acquired in-process research and development		—		-1,202,556
	Foreign tax credit		—		330,000
	Other		644,899		19,241
	Deferred tax asset, excluding valuation allowance		46,282,857		36,270,923
	Less valuation allowance		-46,282,857		-36,270,923
	Net deferred tax assets	$	—	$	—
	There was no current or deferred income tax expense for the year ended December 31, 2013. The Company recorded $330,000 in income tax expense for the year ended December 31, 2012, as a result of South Korean taxes withheld associated with the Ildong sublicense agreement (see Note 8). Income tax expense differed from amounts computed by applying the US Federal income tax rate of 34% to pretax loss as follows:
		For the year ended December 31,
		2013		2012
	Loss before income taxes, as reported in the consolidated statements	$	-20,478,210	$	-25,852,952
	of operations
	Computed “expected” tax benefit	$	-6,962,592	$	-8,790,003
	Increase (decrease) in income taxes resulting from:
	Expected benefit from state and local taxes		-917,810		-1,758,001
	Research and development credits		-250,000		-75,000
	Other		43,026		230,643
	Permanent difference related to contingent note payable		-1,924,558		—
	Foreign tax withholding		—		330,000
	Change in the balance of the valuation allowance for deferred tax		10,011,934		10,392,361
	assets
		$	—	$	330,000
	We file income tax returns in the U.S Federal and various state and local jurisdictions. With certain exceptions, the Company is no longer subject to U.S. Federal and state income tax examinations by tax authorities for years prior to 2010. However, NOLs and tax credits generated from those prior years could still be adjusted upon audit.
	The Company recognizes interest and penalties to uncertain tax position in income tax expense in the statement of operations. There was no accrual for interest and penalties related to uncertain tax positions for 2013. We do not believe that there will be a material change in our unrecognized tax positions over the next twelve months. All of the unrecognized tax benefits, if recognized, would be offset by the valuation allowance.

LICENSE_AGREEMENTS

LICENSE AGREEMENTS	12 Months Ended
	Dec. 31, 2013
License Agreement [Abstract]	'
License Agreement Disclosure [Text Block]	'
	NOTE 8 – LICENSE AGREEMENTS
	TG-1101
	On January 30, 2012, TG Bio entered into an exclusive license agreement with LFB Biotechnologies, GTC Biotherapeutics and LFB/GTC LLC, all wholly-owned subsidiaries of LFB Group, relating to the development of TG-1101 (the “License Agreement”). Under the License Agreement, we acquired the exclusive worldwide rights (exclusive of France/Belgium) for the development and commercialization of TG-1101 (ublituximab). To date, we have made no payments to LFB Group, who is eligible to receive payments of up to an aggregate of approximately $31.0 million upon our successful achievement of certain clinical development, regulatory and sales milestones, in addition to royalty payments on net sales of TG-1101. The license will terminate on a country by country basis upon the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated.
	In connection with the License Agreement, our subsidiary TG Bio issued 7,368,000 shares of its common stock to LFB Group, and the Company agreed to contribute $15 million, less applicable fees and expenses associated with the financing, to TG Bio to fund the development of TG-1101 under the License Agreement in exchange for 7,500,000 shares of TG Bio common stock. The Company recognized $16,578,000 of noncash research and development expense during the year ended December 31, 2012 in connection with the issuance of these shares. In addition, in connection with this share issuance, the Company and TG Bio provided LFB Group the option to, in its sole discretion, elect to convert its shares of TG Bio common stock into 7,500,000 shares of the Company’s Common Stock. Furthermore, should LFB Group choose to exercise the option for Company Common Stock, the Board of Directors of the Company shall appoint an individual designated by LFB Group to serve as a director of the Company until the next annual meeting of the stockholders and until his or her successor has been duly elected. Thereafter the Board of Directors of the Company shall nominate a designee named by LFB Group for election at each annual meeting of the stockholders until such time as LFB Group owns less than 10% of the outstanding Company Common Stock.
	On November 9, 2012, LFB Group exercised their right to exchange their TG Bio common stock for Company Common Stock. The Company and LFB Group entered into a Securities Exchange Agreement pursuant to which, LFB Group agreed to exchange its 7,500,000 shares of the common stock of TG Bio, for 5,000,000 shares of Company Common Stock, and a warrant to purchase an aggregate of 2,500,000 shares of Company Common Stock at a purchase price of $0.001 per share. In addition, upon the occurrence of certain financing conditions, the Securities Exchange Agreement requires LFB Group to purchase at least $750,000 in additional shares of Company Common Stock at a purchase price per share equal to the then current Market Price (as defined therein). In addition on November 9, 2012, in connection with the Securities Exchange Agreement, the Board of Directors (the “Board”) of the Company appointed Dr. Yann Echelard to the Board as LFB Group’s nominee. Effective November 9, 2012, in connection with the aforementioned Securities Exchange Agreement, TG Bio became a wholly owned subsidiary of the Company.
	TG-1101 – Ildong Sublicense
	In November 2012, we entered into an exclusive (within the territory) sublicense agreement with Ildong relating to the development and commercialization of TG-1101 in South Korea and Southeast Asia. Under the terms of the sublicense agreement, Ildong has been granted a royalty bearing, exclusive right, including the right to grant sublicenses, to develop and commercialize TG-1101 in South Korea, Taiwan, Singapore, Indonesia, Malaysia, Thailand, Philippines, Vietnam, and Myanmar.
	An upfront payment of $2,000,000, which was received in December 2012, net of $330,000 of income tax withheld, is being recognized as license revenue on a straight-line basis over the life of the agreement, which is through the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated, and represents the estimated period over which the Company will have certain ongoing responsibilities under the sublicense agreement. The Company recorded license revenue of approximately $152,000 and $19,000 for the years ended December 31, 2013 and 2012, respectively, and, at December 31, 2013 and 2012, has deferred revenue of approximately $1,829,000 and $1,981,000, respectively, associated with this $2,000,000 payment (approximately $152,000 of which has been classified as a current liability at December 31, 2013).
	The Company may receive up to an additional $5.0 million in payments upon the achievement of pre-specified milestones. In addition, upon commercialization, Ildong will make royalty payments to the Company on net sales of TG-1101 in the sublicense territory.
	TGR-1202
	On August 15, 2012, the Company and Rhizen Pharmaceuticals S A (“Rhizen”) entered into an exclusive global agreement to collaborate on the development and commercialization of Rhizen’s lead product candidate (the “Collaboration Agreement”), a novel P13K delta inhibitor, (“TGR-1202”) (previously referred to as RP5264). The companies will jointly develop the product on a worldwide basis, excluding India, initially focusing on indications in the area of hematologic malignancies and autoimmune disease. Beyond TGR-1202, Rhizen would contribute backup molecules providing multiple opportunities for TG to develop differentiated therapies against hematologic cancers and autoimmune diseases.
	The Company will make up-front licensing payments and milestones based on early clinical development, and will be responsible for the costs of clinical development of the product through Phase II, after which the Company and Rhizen will be jointly responsible for all development costs of the product. The Company and Rhizen will each maintain an exclusive option, exercisable at specific times during development, for the Company to license the rights to TGR-1202, in which case Rhizen would be eligible to receive upfront, development, and commercialization milestone payments in addition to milestone payments and royalties tied to net sales of the product, the aggregate of which could exceed $182.5million. Rhizen shall maintain rights to manufacture and supply the product to the Company, and the Company will be responsible for all clinical and regulatory development for TGR-1202 globally.
	In connection with the Collaboration Agreement, the Company incurred upfront milestone payments of $1,000,000 during the year ended December 31, 2012. During the year ended December 31, 2013, the Company recognized a $2,000,000 milestone payment to Rhizen related to the development of TGR-1202. All milestone payments related to this agreement have been included in other research and development expenses in the accompanying consolidated financial statements. Pursuant to the terms of the Collaboration Agreement, should either of the exclusive license options be exercised, Rhizen would be eligible to receive up to an aggregate of $182.5 million upon the successful achievement of certain clinical development, regulatory, and sales based milestones in addition to royalties on net sales of TGR-1202.

JOINT_VENTURE

JOINT VENTURE	12 Months Ended
	Dec. 31, 2013
Equity Method Investments and Joint Ventures [Abstract]	'
Equity Method Investments and Joint Ventures Disclosure [Text Block]	'
	NOTE 9 – JOINT VENTURE
	On April 19, 2011, H Pharmaceuticals K/S (the “Hedrin JV”), of which the Company was a 15% limited partner at the time, filed a demand for arbitration against Thornton & Ross, LTD. (“T&R”) with respect to alleged breaches by T&R of an Exclusive License Agreement (the “Hedrin License”) dated June 28, 2007, which was originally entered into between the Company and T&R, and which the Company assigned in 2008 to the Hedrin JV, with T&R’s consent. The Hedrin JV is seeking damages from T&R in the amount of approximately $7,000,000. The Company was not a party to the initial arbitration demand.
	On May 20, 2011, T&R filed an answer to the arbitration demand in which T&R asserted counterclaims against the Hedrin JV for alleged breaches by the Hedrin JV of the Hedrin License and for declaratory relief that the Hedrin License was properly terminated by T&R. In addition, T&R impleaded an individual (who is not associated with the Company), Nordic Biotech Venture Fund II K/S (an investment fund) and the Company, demanding arbitration against them based on alleged breaches of the Hedrin License and other related claims. In December 2011, the Company was removed by the arbitrator as a party to the arbitration. T&R is seeking damages of approximately $20,000,000.
	The Hedrin JV and T&R held a mediation session in order to avoid the arbitration process. The mediation process did not produce a result. During 2011, Nordic made an additional capital contribution to the Hedrin JV in order to fund the arbitration. As a result of that capital contribution, as of December 31, 2011, the Company owned a 13% interest in the Hedrin JV, and no further information has been available since that date. The arbitration process is ongoing.

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	NOTE 10 – RELATED PARTY TRANSACTIONS
	On December 30, 2011, OPN Capital Markets (“OPNCM”) and its affiliated broker-dealer, National Securities Corporation (“NSC” and collectively with OPNCM, “National”), both affiliates of National Holdings Corporation (“National Holdings”), entered into a Placement Agency Agreement (the “PAA”) with the Company in connection with the initial closing of the 2011 Equity PIPE.  Pursuant to the PAA, National acted as the Company’s placement agent for 2011 Equity PIPE.
	Until April 2012, Michael S. Weiss was a director and Non-Executive Chairman of the Board of Directors of National Holdings.  He is also a stockholder of National Holdings and, when combined with his ownership indirectly through Opus and its affiliates, beneficially owns approximately 5% of National Holdings, the parent company of NSC. Mr. Weiss disclaims such beneficial ownership other than to the extent of his pecuniary interest. In addition, at the time, Opus and NSC were parties to a 50/50 joint venture that shared profits from OPNCM, the investment banking division of NSC that was responsible for managing the Offering. This joint venture was dissolved in April 2012.
	As placement agent, National received cash commissions equal to 10% of the gross proceeds of the 2011 Equity PIPE, five-year warrants to purchase shares of Company Preferred Stock equal to 10% of shares sold in the 2011 Equity PIPE, and a non-accountable expense allowance equal to two percent of the gross proceeds of the 2011 Equity PIPE for National’s expenses (not including up to $80,000 of National’s legal expenses and any blue sky fees, both of which the Company also reimbursed). In connection with the dissolution of the joint venture in January 2013, National waived all rights to and surrendered to Opus the warrants discussed above. In addition to acting as placement agent, National provided advisory services in connection with the Exchange Transaction and received an advisory fee of $150,000 for such services.
	Under the terms of the Company’s License Agreement with LFB Group, the Company utilizes LFB Group for certain development and manufacturing services.  The Company incurred approximately $6,267,000 and $1,447,000 in such expenses during the years ended December 31, 2013 and 2012, respectively, which have been included in other research and development expenses in the accompanying consolidated statements of operations. As of December 31, 2013 and 2012, respectively, the Company has approximately $1,745,000 and $56,000 recorded in accounts payable related to the aforementioned agreements with LFB Group. In conjunction with the development and manufacturing services discussed above, certain agreements between the Company and LFB Group require payments in advance of services performed or goods delivered.  Accordingly, as of December 31, 2013 and 2012, respectively, the Company recorded $1,629,340 and $1,719,828 in prepaid research and development for such advance payments.
	In connection with the Collaboration Agreement with Rhizen in August 2012, the Company issued Opus 2,000,000 shares of Company common stock subject to certain vesting provisions based on the progress of the joint venture and future success of the products governed by the Collaboration Agreement. The issuance of the Company Common Stock was exempt from registration under the Securities Act of 1933 pursuant to Regulation D and Rule 506 promulgated thereunder. Accordingly, the securities have not been registered under the Securities Act, and until so registered, these securities may not be offered or sold in the United States absent registration or availability of an applicable exemption from registration. The Company recognized approximately $437,000 and $134,000 of noncash compensation (research and development) expense during the year ended December 31, 2013 and 2012, respectively, in connection with the issuance of these shares.

ORGANIZATION_AND_SUMMARY_OF_SI1

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Business Description [Policy Text Block]	'
	DESCRIPTION OF BUSINESS
	We are a biopharmaceutical company focused on the acquisition, development and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding their research and development and eventually either out-licensing or bringing the technologies to market. Currently, the Company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab), is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. We are also developing TGR-1202, an orally available PI3K delta inhibitor. We also hold the development rights to AST-726, a nasally delivered product for the treatment of Vitamin B12 deficiency.
	Exchange Transaction with TG Therapeutics, Inc. and its majority shareholders
	On December 29, 2011, the Company entered into and consummated an Exchange Transaction Agreement with Opus Point Partners, LLC (“Opus”) and TG Biologics, Inc. (formerly known as TG Therapeutics, Inc.) (“TG Bio”) (the “Agreement”). Under the Agreement, Opus exchanged (the “Exchange Transaction”) its shares of common stock in TG Bio (“TG Bio Common Stock”) for shares of Series A preferred stock in the Company (“Company Preferred Stock”). In accordance with the terms of the Agreement, 95% of the holders of common stock of TG Bio (one (1) minority shareholder of TG Bio holding in aggregate 132,000 shares of common stock of TG Bio did not participate) surrendered their TG Bio common stock. The Agreement caused the Company to issue to TG Bio’s shareholders 281,250 shares of Company Preferred Stock. Each share of Company Preferred Stock was convertible into 8.89 shares of the Common Stock provided that such conversion rights were subject to sufficient available authorized shares of Common Stock. In connection with the reverse stock split effected by the Company on April 30, 2012 (as discussed below), all shares of preferred stock issued in connection with the Agreement were converted to Common Stock. The Company Preferred Stock issued in connection with the Agreement provided the former TG Bio shareholders with direct and/or indirect ownership of approximately 95% of the Company’s outstanding Company Common Stock immediately following the consummation of the transaction.
	Since the stockholders of TG Bio received the majority of the voting shares of the Company, the merger was accounted for as a reverse acquisition whereby TG Bio was the accounting acquirer (legal acquiree) and the Company was the accounting acquiree (legal acquirer) under the acquisition method of accounting. TG Bio was incorporated in Delaware in November 2010, but did not commence operations until April 2011.
	The filings with the Securities and Exchange Commission (the “SEC”) include the historical financial results of TG Bio and will hereafter collectively be referred to as the Company.
	On April 30, 2012, the Company filed a Certificate of Amendment to its Certificate of Incorporation to change its name from Manhattan Pharmaceuticals, Inc. (“Manhattan”) to TG Therapeutics, Inc. In conjunction with this change, the subsidiary formerly named TG Therapeutics, Inc. filed a Certificate of Amendment changing its name to TG Biologics, Inc.
Liquidity Disclosure [Policy Text Block]	'
	LIQUIDITY AND CAPITAL RESOURCES
	We have incurred operating losses since our inception, and expect to continue to incur operating losses for the foreseeable future and may never become profitable. As of December 31, 2013, we have an accumulated deficit of $39,404,003.
	Our primary source of cash has been proceeds from the sale of equity securities, the upfront payment from our Sublicense Agreement with Ildong Pharmaceutical Co. Ltd. (“Ildong”), and warrant exercises. We have not yet commercialized any of our drug candidates and cannot be sure if we will ever be able to do so. Even if we commercialize one or more of our drug candidates, we may not become profitable. Our ability to achieve profitability depends on a number of factors, including our ability to obtain regulatory approval for our drug candidates, successfully complete any post-approval regulatory obligations and successfully commercialize our drug candidates alone or in partnership. We may continue to incur substantial operating losses even if we begin to generate revenues from our drug candidates.
	As of December 31, 2013, we had $45,431,532 in cash, cash equivalents, investment securities, and interest receivable. We currently anticipate that our cash and cash equivalents to be sufficient to fund our anticipated operating cash requirements for approximately 24 months from December 31, 2013. The actual amount of cash that we will need to operate is subject to many factors, including, but not limited to, the timing, design and conduct of clinical trials for our drug candidates. We are dependent upon significant future financing to provide the cash necessary to execute our current operations, including the commercialization of any of our drug candidates.
	Our common stock is quoted on the NASDAQ Capital Market and trades under the symbol “TGTX.”
Reverse Stock Split [Policy Text Block]	'
	REVERSE STOCK SPLIT
	On April 30, 2012, the Company effected a reverse split of its Common Stock at a ratio of 56.25 for 1, pursuant to a previously obtained stockholder authorization. All share amounts and per share prices in this Annual Report on Form 10-K have been retroactively adjusted to reflect the effect of our reverse stock split, on a fifty-six and one quarter (56.25) for one (1) basis, unless otherwise indicated.  The exercise price for all stock options and warrants and the conversion price for convertible securities in the accompanying consolidated financial statements have been adjusted to reflect the reverse stock split by multiplying the original exercise or conversion price by fifty-six and one quarter (56.25).
New Accounting Pronouncements, Policy [Policy Text Block]	'
	RECENTLY ISSUED ACCOUNTING STANDARDS
	In July 2013, the Financial Accounting Standards Board, or FASB, issued a new accounting standard which will require the presentation of certain unrecognized tax benefits as reductions to deferred tax assets rather than as liabilities in the consolidated balance sheets when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The new standard requires adoption on a prospective basis in the first quarter of 2015; however, early adoption is permitted. The Company does not anticipate that this adoption will have a significant impact on its financial position, results of operations, or cash flows.
	Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to the consolidated financial statements of the Company.
Basis of Accounting, Policy [Policy Text Block]	'
	BASIS OF PRESENTATION
	The Company has generated limited revenue from its operations and, accordingly, the financial statements have been prepared in accordance with the provisions of accounting and reporting for Development Stage Enterprises.
Use of Estimates, Policy [Policy Text Block]	'
	USE OF ESTIMATES
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the applicable reporting period. Actual results could differ from those estimates. Such differences could be material to the financial statements.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	CASH AND CASH EQUIVALENTS
	We treat liquid investments with original maturities of less than three months when purchased as cash and cash equivalents.
Marketable Securities, Policy [Policy Text Block]	'
	INVESTMENT SECURITIES
	Investment securities at December 31, 2013 consist of long-term government securities. We classify our long-term debt securities as held-to-maturity. Held-to-maturity securities are those securities in which we have the ability and intent to hold the security until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized or accreted over the life of the related held-to-maturity security as an adjustment to yield using the effective interest method.
	A decline in the market value of any investment security below cost, that is deemed to be other than temporary, results in a reduction in the carrying amount to fair value. The impairment is charged to operations and a new cost basis for the security is established. Other-than-temporary impairment charges are included in interest and other income, net. Unrealized gains, if determined to be temporary, are included in accumulated other comprehensive income in stockholders’ equity. Dividend and interest income are recognized when earned.
Revenue Recognition, Policy [Policy Text Block]	'
	REVENUE RECOGNITION
	We recognize license revenue in accordance with the revenue recognition guidance of the FASB Accounting Standards Codification, or Codification. We analyze each element of our licensing agreement to determine the appropriate revenue recognition. The terms of the license agreement may include payments to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. We recognize revenue from upfront payments over the period of significant involvement under the related agreements unless the fee is in exchange for products delivered or services rendered that represent the culmination of a separate earnings process and no further performance obligation exists under the contract. We recognize milestone payments as revenue upon the achievement of specified milestones only if (1) the milestone payment is non-refundable, (2) substantive effort is involved in achieving the milestone, (3) the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone, and (4) the milestone is at risk for both parties. If any of these conditions are not met, we defer the milestone payment and recognize it as revenue over the estimated period of performance under the contract.
Research and Development Expense, Policy [Policy Text Block]	'
	RESEARCH AND DEVELOPMENT COSTS
	Generally, research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are delivered or the related services are performed, subject to an assessment of recoverability. We make estimates of costs incurred in relation to external clinical research organizations, or CROs, and clinical site costs. We analyze the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and estimates must be made and used in determining the accrued balance and expense in any accounting period. We review and accrue CRO expenses and clinical trial study expenses based on work performed and rely upon estimates of those costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under these contracts may be uneven, and depend on factors such as the achievement of certain events, the successful recruitment of patients, the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the recording of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical study or trial contract.
In Process Research and Development, Policy [Policy Text Block]	'
	IN-PROCESS RESEARCH AND DEVELOPMENT
	All acquired research and development projects are recorded at their fair value as of the date acquisition. The fair values are assessed as of the balance sheet date to ascertain if there has been any impairment of the recorded value. If there is an impairment, the asset is written down to its current fair value by the recording of an expense. Impairment is tested on an annual basis or sooner, if there is an indication of impairment, and consists of a comparison of the fair value of the in-process research and development with its carrying amount.
Income Tax, Policy [Policy Text Block]	'
	INCOME TAXES
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. If the likelihood of realizing the deferred tax assets or liability is less than “more likely than not,” a valuation allowance is then created.
	We, and our subsidiaries, file income tax returns in the U.S. Federal jurisdiction and in various states. We have tax net operating loss carryforwards that are subject to examination for a number of years beyond the year in which they were generated for tax purposes. Since a portion of these net operating loss carryforwards may be utilized in the future, many of these net operating loss carryforwards will remain subject to examination.
	We recognize interest and penalties related to uncertain income tax positions in income tax expense.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	STOCK - BASED COMPENSATION
	We recognize all share-based payments to employees and to non-employee directors as compensation for service as compensation expense in the consolidated financial statements based on the fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
	For share-based payments to consultants and other third-parties, compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date. The awards to consultants and other third-parties are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent reporting date.
Earnings Per Share, Policy [Policy Text Block]	'
	BASIC AND DILUTED NET (LOSS) INCOME PER COMMON SHARE
	Basic net income (loss) per common share is calculated by dividing net income (loss) applicable to common shares by the weighted-average number of common shares outstanding for the period. Diluted net loss per common share is the same as basic net income (loss) per common share, since potentially dilutive securities from stock options, stock warrants and convertible preferred stock would have an antidilutive effect either because the Company incurred a net loss during the period presented or because such potentially dilutive securities were out of the money and the Company realized net income during the period presented. The amounts of potentially dilutive securities excluded from the calculation were 10,618,584 and 10,746,837 at December 31, 2013 and 2012, respectively. During the years ended December 31, 2013 and 2012 the Company incurred a net loss, therefore, all of the dilutive securities are excluded from the computation of diluted earnings per share.
Impairment Of Tangible and Intangible Asset Including Goodwill [Policy Text Block]	'
	LONG-LIVED ASSETS AND GOODWILL
	Long-lived assets are reviewed for an impairment loss when circumstances indicate that the carrying value of long-lived tangible and intangible assets with finite lives may not be recoverable. Management’s policy in determining whether an impairment indicator exists, a triggering event, comprises measurable operating performance criteria as well as qualitative measures. If an analysis is necessitated by the occurrence of a triggering event, we make certain assumptions in determining the impairment amount. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized.
	Goodwill is reviewed for impairment annually, or when events arise that could indicate that an impairment exists. We test for goodwill impairment using a two-step process. The first step compares the fair value of the reporting unit with the unit's carrying value, including goodwill. When the carrying value of the reporting unit is greater than fair value, the unit’s goodwill may be impaired, and the second step must be completed to measure the amount of the goodwill impairment charge, if any. In the second step, the implied fair value of the reporting unit’s goodwill is compared with the carrying amount of the unit’s goodwill. If the carrying amount is greater than the implied fair value, the carrying value of the goodwill must be written down to its implied fair value. We will continue to perform impairment tests annually, at December 31, and whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable.

CASH_AND_CASH_EQUIVALENTS_Tabl

CASH AND CASH EQUIVALENTS (Tables)	12 Months Ended
	Dec. 31, 2013
Cash and Cash Equivalents [Abstract]	'
Schedule of Cash and Cash Equivalents [Table Text Block]	'
		December 31, 2013		December 31, 2012
	Money market funds	$	554,069	$	500,007
	Checking and bank deposits		39,931,397		15,955,988
	Total	$	40,485,466	$	16,455,995

INVESTMENT_SECURITIES_Tables

INVESTMENT SECURITIES (Tables)	12 Months Ended
	Dec. 31, 2013
Investments, Debt and Equity Securities [Abstract]	'
Held-to-maturity Securities [Table Text Block]	'
	The following tables summarize our investment securities at December 31, 2013:
		December 31, 2013
		Amortized cost,		Gross		Gross		Estimated
		as adjusted		unrealized		unrealized		fair value
				holding gains		holding losses
	Long-term investments:
	Obligations of domestic governmental agencies	$	4,918,897	$	—	$	650	$	4,918,247
	(maturing between January 2015 and April 2015) (held-to-maturity)
	Total long-term investment securities	$	4,918,897	$	—	$	650	$	4,918,247

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]	'
	The Company’s financial liabilities measured at fair value on a recurring basis as of December 31, 2013 and 2012 were as follows:
			Financial liabilities at fair value
			as of December 31, 2013
			Level 1			Level 2			Level 3			Total
	5% Notes		$	—		$	—		$	64,529		$	64,529
	Totals		$	—		$	—		$	64,529		$	64,529
		Financial liabilities at fair value
		as of December 31, 2012
		Level 1			Level 2			Level 3			Total
	5% Notes	$	—		$	—		$	2,479,098		$	2,479,098
	Totals	$	—		$	—		$	2,479,098		$	2,479,098
Change In Level Three Fair Value During Period [Table Text Block]	'
	The following table summarizes the changes in Level 3 instruments for the years ended December 31, 2012 and 2013:
	Balance at January 1, 2012	$	3,294,797
	Interest accrued on face value of 5% Notes		844,173
	Change in fair value of Level 3 liabilities		-1,659,872
	Balance at December 31, 2012		2,479,098
	Interest accrued on face value of 5% Notes		886,382
	Change in fair value of Level 3 liabilities		-3,300,951
	Balance at December 31, 2013	$	64,529
Fair Value Measurements, Nonrecurring [Table Text Block]	'
	The Company’s assets measured at fair value on a nonrecurring basis as of December 31, 2013 and 2012 were as follows:
		Fair value measurements										Total impairment charge  for the year ended
		as of December 31, 2013
		Level 1			Level 2			Level 3				December 31, 2013
	Assets:
	In-process research and development	$	—		$	—		$	—		$	-2,797,600
	Total	$	—		$	—		$	—		$	-2,797,600
		Fair value measurements										Total impairment charge for the year ended
		as of December 31, 2012
		Level 1			Level 2			Level 3				December 31, 2012
	Assets:
	In-process research and development	$	—		$	—		$	2,797,600		$	-1,104,700
	Total	$	—		$	—		$	2,797,600		$	-1,104,700

STOCKHOLDERS_EQUITY_Tables

STOCKHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2013
Stockholders Equity [Line Items]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table summarizes stock option activity for the years ended December 31, 2013 and 2012:
		Number		Weighted-			Weighted-		Aggregate Intrinsic
		of shares		average			average		Value
				exercise price			Contractual
							Term
							(in years)
	Outstanding at January 1, 2012	3,379		$	1,315.62
	Granted	46,000			4.4
	Exercised	—			—
	Forfeited	-2,475			720.45
	Expired	—			—
	Outstanding at December 31, 2012	46,904			61.08		9.44		$	—
	Granted	—			—
	Exercised	—			—
	Forfeited	-313			2,249.85
	Expired	—			—
	Outstanding at December 31, 2013	46,591		$	46.37		8.5		$	—
	Vested and expected to vest at December 31, 2013	9,591		$	208.3		8.16		$	—
	Exercisable at December 31, 2013	9,591		$	208.3		8.16		$	—
Schedule Of Warrants Activity [Table Text Block]	'
	The following table summarizes warrant activity for the years ended December 31, 2013 and 2012:
		Warrants		Weighted-			Aggregate
				average			Intrinsic
				exercise price			Value
	Outstanding at January 1, 2012	1,625,911			5.27		$	—
	Issued	5,156,599			1.21
	Exercised	—			—
	Expired	-1,503			2,739.75
	Outstanding at December 31, 2012	6,781,007			1.58		$	14,563,539
	Issued	—			—
	Exercised	-1,018,068			2.25
	Expired	-43,992			16.26
	Outstanding at December 31, 2013	5,718,947		$	1.34		$	14,809,030
Schedule Of Share Based Compensation Expense [Table Text Block]	'
	The following table summarizes stock-based compensation expense information about stock options and restricted stock for the years ended December 31, 2013 and 2012:
		2013			2012
	Stock-based compensation expense associated with restricted stock	$	5,146,743		$	3,422,182
	Stock-based compensation expense associated with option grants		56,405			—
		$	5,203,148		$	3,422,182
Preferred Restricted Stock [Member]	'
Stockholders Equity [Line Items]	'
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	'
	Certain employees had been awarded restricted preferred stock. The restricted stock vesting consisted of milestone and time-based vesting. The following table summarizes restricted share activity for the years ended December 31, 2013 and 2012:
		Number of Shares		Weighted
		Restricted Series		Average
		A Preferred		Grant Date
		Stock(1)		Fair Value
	Outstanding at January 1, 2012	129,375		$	20
	Granted	—			—
	Vested	—			—
	Forfeited	—			—
	Conversion to restricted common stock	-129,375			20
	Outstanding at December 31, 2012	—			—
	Granted	—			—
	Vested	—			—
	Forfeited	—			—
	Outstanding at December 31, 2013	—		$	—
	(1)  The restricted preferred stock listed in the table above was granted in connection with the Exchange Transaction to certain executives. Each share of preferred stock was convertible into 8.89 shares of the Company’s Common Stock. In conjunction with the reverse split effected on April 30, 2012 (as discussed in Note 1), all outstanding restricted Preferred Stock automatically converted to 1,150,000 shares of restricted Common Stock as of that date.
Common Restricted Stock [Member]	'
Stockholders Equity [Line Items]	'
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	'
	Certain employees, directors and consultants have been awarded restricted Company Common Stock. The restricted stock vesting consists of milestone and time-based vesting. The following table summarizes restricted share activity for the years ended December 31, 2013 and 2012:
		Number of Shares		Weighted
				Average
				Grant Date
				Fair Value
	Outstanding at January 1, 2012	—		$	—
	Converted preferred stock	1,150,000			2.25
	Granted	5,901,743			4.77
	Vested	-437,500			2.25
	Forfeited	—			—
	Outstanding at December 31, 2012	6,614,243			4.49
	Granted	944,464			4.13
	Vested	-523,750			2.48
	Forfeited	—			—
	Outstanding at December 31, 2013	7,034,957		$	4.6

NOTES_PAYABLE_Tables

NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Schedule of Debt [Table Text Block]	'
	The following is a summary of notes payable:
		December 31, 2013						December 31, 2012
		Current		Non-current		Total		Current		Non-current		Total
		portion, net		portion,				portion, net		portion,
				net						net
	Convertible 5% Notes Payable	$	-	$	64,529	$	64,529	$	-	$	2,479,098	$	2,479,098
	ICON Convertible Note		677,778		-		677,778		677,778		-		677,778
	Totals	$	677,778	$	64,529	$	742,307	$	677,778	$	2,479,098	$	3,156,876

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
	The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2013 and 2012 are presented below.
		2013		2012
	Deferred tax assets (liabilities):
	Net operating loss carryforwards	$	32,399,879	$	32,190,080
	Research and development credit		2,266,167		1,882,238
	Noncash compensation		10,971,912		3,051,920
	Acquired in-process research and development		—		-1,202,556
	Foreign tax credit		—		330,000
	Other		644,899		19,241
	Deferred tax asset, excluding valuation allowance		46,282,857		36,270,923
	Less valuation allowance		-46,282,857		-36,270,923
	Net deferred tax assets	$	—	$	—
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
	Income tax expense differed from amounts computed by applying the US Federal income tax rate of 34% to pretax loss as follows:
		For the year ended December 31,
		2013		2012
	Loss before income taxes, as reported in the consolidated statements	$	-20,478,210	$	-25,852,952
	of operations
	Computed “expected” tax benefit	$	-6,962,592	$	-8,790,003
	Increase (decrease) in income taxes resulting from:
	Expected benefit from state and local taxes		-917,810		-1,758,001
	Research and development credits		-250,000		-75,000
	Other		43,026		230,643
	Permanent difference related to contingent note payable		-1,924,558		—
	Foreign tax withholding		—		330,000
	Change in the balance of the valuation allowance for deferred tax		10,011,934		10,392,361
	assets
		$	—	$	330,000

ORGANIZATION_AND_SUMMARY_OF_SI2

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) (USD $)	1 Months Ended	12 Months Ended			1 Months Ended
	Apr. 30, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 29, 2011	Dec. 29, 2011	Dec. 29, 2011
					Tg Bio [Member]	Tg Bio [Member]
						Preferred Stock [Member]
Significant Accounting Policies [Line Items]	'	'	'	'	'	'
Business Acquisition Shares Repurchased Percentage	'	'	'	95.00%	'	'
Deficit accumulated in development stage	'	$39,404,003	$18,925,793	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	'	10,618,584	10,746,837	'	'	'
Period Anticipated Sufficient To Fund Operating Cash Flow	'	'24 months	'	'	'	'
Business Acquisition Shares Not Surrendered	'	'	'	'	132,000	'
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	'	'	'	'	281,250	'
Convertible Preferred Stock, Shares Issued upon Conversion	'	8.89	'	'	'	8.89
Percentage Of Stock Issued After Exchange Transaction	'	'	'	'	95.00%	'
Cash, Cash Equivalents, and Short-term Investments, Total	'	$45,431,532	'	'	'	'
Stockholders Equity, Reverse Stock Split	'ratio of 56.25 for 1	'	'	'	'	'
Cash Equivalents Maturity Period	'	'less than three months	'	'	'	'

CASH_AND_CASH_EQUIVALENTS_Deta

CASH AND CASH EQUIVALENTS (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Nov. 30, 2011
Cash and Cash Equivalents [Line Items]	'	'	'	'
Money market funds	$554,069	$500,007	'	'
Checking and bank deposits	39,931,397	15,955,988	'	'
Total	$40,485,466	$16,455,995	$9,748,491	$0

INVESTMENT_SECURITIES_Details

INVESTMENT SECURITIES (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Schedule of Held-to-maturity Securities [Line Items]	'
Amortized cost, as adjusted	$4,918,897
Gross unrealized holding gains	0
Gross unrealized holding losses	650
Estimated fair value	4,918,247
US Government Agencies Debt Securities [Member]	'
Schedule of Held-to-maturity Securities [Line Items]	'
Amortized cost, as adjusted	4,918,897
Gross unrealized holding gains	0
Gross unrealized holding losses	650
Estimated fair value	$4,918,247

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
5% Notes	$64,529	$2,479,098
Totals	64,529	2,479,098
Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
5% Notes	0	0
Totals	0	0
Fair Value, Inputs, Level 2 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
5% Notes	0	0
Totals	0	0
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
5% Notes	64,529	2,479,098
Totals	$64,529	$2,479,098

FAIR_VALUE_MEASUREMENTS_Detail1

FAIR VALUE MEASUREMENTS (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Measurement Changes In Level 3 Instruments [Line Items]	'	'
Balance at January	$2,479,098	$3,294,797
Interest accrued on face value of 5% Notes	886,382	844,173
Change in fair value of Level 3 liabilities	-3,300,951	-1,659,872
Balance at December	$64,529	$2,479,098

FAIR_VALUE_MEASUREMENTS_Detail2

FAIR VALUE MEASUREMENTS (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Asset Impairment Charges, Total	($2,797,600)	($1,104,700)
In Process Research and Development [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Asset Impairment Charges, Total	-2,797,600	-1,104,700
Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Assets, Fair Value Disclosure, Nonrecurring	0	0
Fair Value, Inputs, Level 1 [Member] | In Process Research and Development [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Assets, Fair Value Disclosure, Nonrecurring	0	0
Fair Value, Inputs, Level 2 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Assets, Fair Value Disclosure, Nonrecurring	0	0
Fair Value, Inputs, Level 2 [Member] | In Process Research and Development [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Assets, Fair Value Disclosure, Nonrecurring	0	0
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Assets, Fair Value Disclosure, Nonrecurring	0	2,797,600
Fair Value, Inputs, Level 3 [Member] | In Process Research and Development [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Assets, Fair Value Disclosure, Nonrecurring	$0	$2,797,600

FAIR_VALUE_MEASUREMENTS_Detail3

FAIR VALUE MEASUREMENTS (Details Textual) (USD $)	12 Months Ended		25 Months Ended		1 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2011	Mar. 31, 2010
					Manhattan and Ariston Pharmaceuticals Merger [Member]
Fair Value Measurement [Line Items]	'	'	'	'	'
Notes Issued	'	'	'	'	$15,452,793
Debt Instrument, Interest Rate, Effective Percentage	5.00%	5.00%	5.00%	'	5.00%
Debt Instrument, Convertible, Conversion Price	'	'	'	'	$1,125
Percentage Of Cash Proceeds From Operation To Repay Convertible Debt	'	'	'	'	50.00%
Long-term Debt, Gross	18,614,000	17,727,000	18,614,000	16,876,000	'
Debt Instrument, Fair Value Disclosure	'	'	'	3,287,700	'
Fair Value Inputs, Discount Rate	'	20.00%	'	'	'
Impairment Of In Process Research And Development	$2,797,600	$1,104,700	$3,902,300	'	'
Debt Instrument Maturity Period	'	'	'	'	'5 years

STOCKHOLDERS_EQUITY_Details

STOCKHOLDERS' EQUITY (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Equity Incentive Plans Stock Option Activity [Line Items]	'	'
Number of shares, Outstanding Beginning Balance	46,904	3,379
Number of shares, Granted	0	46,000
Number of shares, Exercised	0	0
Number of shares, Forfeited	-313	-2,475
Number of shares, Expired	0	0
Number of shares, Outstanding Ending Balance	46,591	46,904
Number of shares, Vested and expected to vest Ending Balance	9,591	'
Number of shares, Exercisable Ending Balance	9,591	'
Weighted average exercise price, Outstanding Beginning Balance	$61.08	$1,315.62
Weighted-average exercise price, Granted	$0	$4.40
Weighted-average exercise price, Exercised	$0	$0
Weighted-average exercise price, Forfeited	$2,249.85	$720.45
Weighted-average exercise price, Expired	$0	$0
Weighted-average exercise price, Outstanding Ending Balance	$46.37	$61.08
Weighted-average exercise price, Vested and expected to vest Ending Balance	$208.30	'
Weighted-average exercise price, Exercisable Ending Balance	$208.30	'
Weighted-average Contractual Term, Outstanding Beginning Balance	'	'9 years 5 months 8 days
Weighted-average Contractual Term, Outstanding Ending Balance	'8 years 6 months	'
Weighted-average Contractual Term, Vested and expected to vest Ending Balance	'8 years 1 month 28 days	'
Weighted-average Contractual Term, Exercisable Ending Balance	'8 years 1 month 28 days	'
Aggregate Intrinsic Value, Outstanding Beginning Balance	'	$0
Aggregate Intrinsic Value, Outstanding Ending Balance	0	'
Aggregate Intrinsic Value, Vested and expected to vest Ending Balance	0	'
Aggregate Intrinsic Value, Exercisable Ending Balance	$0	'

STOCKHOLDERS_EQUITY_Details_1

STOCKHOLDERS' EQUITY (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012
Restricted Series A Preferred [Member]	'		'
Equity Incentive Plans Restricted Stock Activity [Line Items]	'		'
Number of Shares, Outstanding at Beginning Balance	0	[1]	129,375	[1]
Number of Shares, Granted	0	[1]	0	[1]
Number of Shares, Vested	0	[1]	0	[1]
Number of Shares, Forfeited	0	[1]	0	[1]
Conversion to restricted common stock Ending Balance	'		-129,375	[1]
Number of Shares, Outstanding Ending Balance	0	[1]	0	[1]
Weighted Average Grant Date Fair Value, Outstanding Beginning Balance	$0		$20
Weighted Average Grant Date Fair Value, Granted	$0		$0
Weighted Average Grant Date Fair Value, Vested	$0		$0
Weighted Average Grant Date Fair Value, Forfeited	$0		$0
Weighted Average Grant Date Fair Value, Outstanding Ending Balance	$0		$0
Conversion to restricted common stock, Weighted average grant date fair value Ending Balance	'		$20
Restricted Common Stock [Member]	'		'
Equity Incentive Plans Restricted Stock Activity [Line Items]	'		'
Number of Shares, Outstanding at Beginning Balance	6,614,243		0
Number of Shares, Granted	944,464		5,901,743
Number of Shares, Vested	-523,750		-437,500
Number of Shares, Forfeited	0		0
Conversion to restricted common stock Ending Balance	'		1,150,000
Number of Shares, Outstanding Ending Balance	7,034,957		6,614,243
Weighted Average Grant Date Fair Value, Outstanding Beginning Balance	$4.49		$0
Weighted Average Grant Date Fair Value, Granted	$4.13		$4.77
Weighted Average Grant Date Fair Value, Vested	$2.48		$2.25
Weighted Average Grant Date Fair Value, Forfeited	$0		$0
Weighted Average Grant Date Fair Value, Outstanding Ending Balance	$4.60		$4.49
Conversion to restricted common stock, Weighted average grant date fair value Ending Balance	'		$2.25
[1]	The restricted preferred stock listed in the table above was granted in connection with the Exchange Transaction to certain executives. Each share of preferred stock was convertible into 8.89 shares of the Companybs Common Stock. In conjunction with the reverse split effected on April 30, 2012 (as discussed in Note 1), all outstanding restricted Preferred Stock automatically converted to 1,150,000 shares of restricted Common Stock as of that date.

STOCKHOLDERS_EQUITY_Details_2

STOCKHOLDERS' EQUITY (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Equity Incentive Plans Warrant Activity [Line Items]	'	'
Warrants, Outstanding Beginning Balance	6,781,007	1,625,911
Warrants, Issued	0	5,156,599
Warrants, Exercised	-1,018,068	0
Warrants, Expired	-43,992	-1,503
Warrants, Outstanding Ending Balance	5,718,947	6,781,007
Weighted - Average exercise price of Warrants, Outstanding Beginning Balance Beginning Balance	$1.58	$5.27
Weighted - Average exercise price of Warrants, Issued	$0	$1.21
Weighted - Average exercise price of Warrants, Exercised	$2.25	$0
Weighted - Average exercise price of Warrants, Expired	$16.26	$2,739.75
Weighted - Average exercise price of Warrants, Outstanding Ending Balance	$1.34	$1.58
Aggregate Intrinsic Value of Warrants, Outstanding Beginning Balance	$14,563,539	$0
Aggregate Intrinsic Value of Warrants, Outstanding Ending Balance	$14,809,030	$14,563,539

STOCKHOLDERS_EQUITY_Details_3

STOCKHOLDERS' EQUITY (Details 3) (USD $)	12 Months Ended		25 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Stock Based Compensation [Line Items]	'	'	'
Stock compensation expense	$5,203,148	$3,422,182	$8,711,824
Employee Stock Option [Member]	'	'	'
Stock Based Compensation [Line Items]	'	'	'
Stock-based compensation expense associated with option grants	56,405	0	'
Restricted Stock [Member]	'	'	'
Stock Based Compensation [Line Items]	'	'	'
Stock-based compensation expense associated with restricted stock	$5,146,743	$3,422,182	'

STOCKHOLDERS_EQUITY_Details_Te

STOCKHOLDERS' EQUITY (Details Textual) (USD $)

1 Months Ended

12 Months Ended

25 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

Jul. 18, 2013

Apr. 30, 2012

Feb. 24, 2012

Dec. 30, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2011

Apr. 19, 2011

Dec. 31, 2013

Apr. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Nov. 09, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

31-May-12

Dec. 31, 2013

Apr. 30, 2012

Warrant [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Non Employee Restricted Stock [Member]

Corporate Milestone [Member]

Placement Agent [Member]

Lfb [Member]

Lfb [Member]

Tg Bio [Member]

Restricted Stock [Member]

Restricted Stock [Member]

2012 Incentive Plan [Member]

2012 Incentive Plan [Member]

Equity Incentive Plans [Member]

Series A Preferred Stock [Member]

Stockholders Equity [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, shares authorized

'

'

'

'

10,000,000

10,000,000

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares Authorized

'

'

'

'

500,000,000

500,000,000

500,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, par value (in dollars per share)

'

'

'

'

$0.00

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, par value (in dollars per share)

'

'

'

'

$0.00

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,107,793

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 year 10 months 24 days

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized

'

'

'

'

$7,977,072

'

$7,977,072

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share Based Compensation Non Employee Stock Options Outstanding

'

'

'

'

37,000

'

37,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance

'

'

'

'

46,591

46,904

46,591

3,379

'

'

'

'

'

'

2,556,375

1,800,960

'

'

'

'

'

'

46,000

'

591

'

Stock Issued During Period Shares New Issues, Shelf registration statement

'

'

'

'

135,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

5,700,000

'

695,428

'

'

'

'

'

'

'

'

6,555,000

'

4,929,523

'

'

'

'

'

'

'

'

'

'

'

'

Share Price

$6.15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds From Issuance Of Common Stock

35,000,000

'

'

'

37,648,280

0

47,472,962

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period Shares New Issues, Overallotments

855,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net Proceeds From Shares New Issues Over-Allotments

37.6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Underwriting discounts and offering expenses

2,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation, Total

'

'

'

'

5,203,148

3,422,182

8,711,824

'

'

'

'

'

'

'

'

'

'

'

'

'

5,146,743

3,422,182

'

'

'

'

Fair Value Per Share Issued

'

'

'

$2.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Private Placement

'

'

13,908,560

11,091,425

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

1,545,396

'

1,232,381

2,777,962

'

2,777,962

'

'

'

'

'

'

'

'

'

1,111,111

2,500,000

2,500,000

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

2.25

'

2.25

2.25

'

2.25

'

'

'

'

'

'

'

'

'

2.48

0.001

0.001

'

'

'

'

'

'

'

Class Of Warrant Or Rights Exercisable Period

'

'5 years

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock, Shares Issued upon Conversion

'

'

'

'

8.89

'

8.89

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.89

Preferred Stock, Liquidation Preference Per Share

'

'

$20

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Treasury Stock, Shares

'

'

'

'

41,309

13,526

41,309

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,000,000

5,333

'

Share Based Compensation Arrangement By Share Based Payment Award Options Maximum Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

Share Based Compensation Arrangement By Share Based Payment Award Options Issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10

'

Conversion of Stock, Shares Converted

'

'

'

'

'

'

'

'

'

'

'

'

9,857,596

'

'

'

'

7,500,000

'

'

'

'

'

'

'

'

Conversion of Stock, Shares Issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

Equity Method Investment, Ownership Percentage

'

'

'

'

'

'

'

13.00%

15.00%

'

'

'

'

'

'

'

'

'

'

42.90%

'

'

'

'

'

'

Equity Method Investments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,479,000

'

'

'

'

'

'

'

Treasury Stock, Value

'

'

'

'

$234,337

$84,538

$234,337

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised

'

'

'

'

'

'

'

'

'

757,096

'

'

'

'

'

'

6,533

'

'

'

'

'

'

'

'

'

Stock Issued During Period Shares Of Replacement Restricted Preferred Stock To Employees

'

'

'

'

'

'

'

'

'

'

1,150,000

'

'

-1,150,000

'

'

'

'

'

'

'

'

'

'

'

'

NOTES_PAYABLE_Details

NOTES PAYABLE (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Notes Payable [Line Items]	'	'
Notes payable, Current portion, net	$677,778	$677,778
Notes payable, Non-current portion, net	64,529	2,479,098
Totals	742,307	3,156,876
Convertible Notes [Member]	'	'
Notes Payable [Line Items]	'	'
Notes payable, Current portion, net	0	0
Notes payable, Non-current portion, net	64,529	2,479,098
Totals	64,529	2,479,098
ICON Convertible Notes [Member]	'	'
Notes Payable [Line Items]	'	'
Notes payable, Current portion, net	677,778	677,778
Notes payable, Non-current portion, net	0	0
Totals	$677,778	$677,778

NOTES_PAYABLE_Details_Textual

NOTES PAYABLE (Details Textual) (USD $)

12 Months Ended

25 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2011

Mar. 08, 2010

Jan. 23, 2014

Mar. 08, 2010

Apr. 30, 2010

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Mar. 31, 2011

Mar. 31, 2011

Convertible Notes Payable [Member]

Icon Clinical Research [Member]

Icon Clinical Research [Member]

Icon Clinical Research [Member]

Icon Clinical Research [Member]

Icon Clinical Research [Member]

Icon Clinical Research [Member]

Ariston [Member]

Exchange Transaction [Member]

Before Amendment [Member]

After Amendment [Member]

Icon Clinical Research [Member]

Icon Clinical Research [Member]

Notes Payable [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

'

'

'

5.00%

'

5.00%

'

'

5.00%

'

5.00%

8.00%

Percentage Of Cash Proceeds From Operation To Repay Interest On Convertible Debt

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

Debt Instrument, Convertible, Conversion Price

'

'

'

'

$1,125

'

'

'

'

'

'

'

'

'

$562.50

Long-term Debt, Gross

$18,614,000

$17,727,000

$18,614,000

$16,876,000

'

'

'

'

'

'

'

'

'

'

'

Accounts Payable

'

'

'

'

'

'

1,275,188

'

'

'

'

'

'

'

'

Payments of short-term loans

0

200,001

200,001

'

'

'

275,188

'

'

'

'

'

'

'

'

Debt Instrument, Periodic Payment, Principal

'

'

'

'

'

'

'

27,778

'

'

'

'

'

'

'

One Time Settlement Amount For Waiver Of Interest and Principal Payments

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

Interest and Debt Expense

'

'

'

'

'

'

'

'

66,506

'

'

'

'

'

'

Notes Payable, Current, Total

677,778

677,778

677,778

'

'

'

'

'

677,778

677,778

'

'

'

'

'

Interest Payable

'

'

'

'

'

'

'

'

190,017

123,511

'

'

'

'

'

Notes Payable, Total

742,307

3,156,876

742,307

'

'

'

'

'

'

'

'

'

3,287,700

'

'

Debt Instrument Repayment Term

'

'

'

'

'

'

'

'36 monthly

'

'

'

'

'

'

'

Debt Instrument, Maturity Date

'

'

'

'

8-Mar-15

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Term

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

Debt Instrument Settlement Of Principal And Interest

'

'

'

'

'

$772,369

'

'

'

'

'

'

'

'

'

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets (liabilities):	'	'
Net operating loss carryforwards	$32,399,879	$32,190,080
Research and development credit	2,266,167	1,882,238
Noncash compensation	10,971,912	3,051,920
Acquired in-process research and development	0	-1,202,556
Foreign tax credit	0	330,000
Other	644,899	19,241
Deferred tax asset, excluding valuation allowance	46,282,857	36,270,923
Less valuation allowance	-46,282,857	-36,270,923
Net deferred tax assets	$0	$0

INCOME_TAXES_Details_1

INCOME TAXES (Details 1) (USD $)	12 Months Ended		25 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Deferred Tax Assets And Liabilities [Line Items]	'	'	'
Loss before income taxes, as reported in the consolidated statements of operations	($20,478,210)	($25,852,952)	($47,220,233)
Computed bexpectedb tax benefit	-6,962,592	-8,790,003	'
Increase (decrease) in income taxes resulting from:	'	'	'
Expected benefit from state and local taxes	-917,810	-1,758,001	'
Research and development credits	-250,000	-75,000	'
Other	43,026	230,643	'
Permanent difference related to contingent note payable	-1,924,558	0	'
Foreign tax withholding	0	330,000	'
Change in the balance of the valuation allowance for deferred tax assets	10,011,934	10,392,361	'
Income Tax Expense (Benefit)	$0	$330,000	$330,000

INCOME_TAXES_Details_Textual

INCOME TAXES (Details Textual) (USD $)	12 Months Ended		25 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Deferred Tax Assets And Liabilities [Line Items]	'	'	'
Deferred Tax Assets, Valuation Allowance	$46,282,857	$36,270,923	$46,282,857
Income Tax Expense (Benefit)	0	330,000	330,000
Us Federal Income Tax [Member]	'	'	'
Deferred Tax Assets And Liabilities [Line Items]	'	'	'
Operating Loss Carryforwards	$84,182,000	'	$84,182,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%	'	'
Operating Loss Carryforwards Expiration Period	'2033	'	'

LICENSE_AGREEMENTS_Details_Tex

LICENSE AGREEMENTS (Details Textual) (USD $)	12 Months Ended		25 Months Ended			0 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Apr. 30, 2012	Dec. 30, 2011	Nov. 09, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
						Lfb Biotechnologies [Member]	Lfb Biotechnologies [Member]	Collaboration Agreement [Member]	Collaboration Agreement [Member]
License Agreement [Line Items]	'	'	'	'	'	'	'	'	'
License revenue	$152,381	$19,048	$171,429	'	'	'	'	'	'
Deferred Revenue	1,829,000	1,981,000	1,829,000	'	'	'	'	'	'
Additional Amount Receivable On Achievement Of Pre Specified Milestones	5,000,000	'	'	'	'	'	'	'	'
Income taxes	0	330,000	330,000	'	'	'	'	'	'
Possible Milestone Payments	'	'	'	'	'	'	31,000,000	'	1,000,000
Bussiness Acquisiton Purchase Agreement Period Description	'	'	'	'	'	'	'The license will terminate on a country by country basis upon the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated.	'	'
Sale of Stock, Number of Shares Issued in Transaction	'	'	'	'	'	'	7,368,000	'	'
Contribution Per Licence Agreement In Exchange Of Common Stock	'	'	'	'	'	'	15,000,000	'	'
Common Stock Shares Subscribed Subsidiary Sale Of Stock	'	'	'	'	'	'	7,500,000	'	'
Shares Issued For Licence Agreement Exchange	'	'	'	'	'	'	7,500,000	'	'
Non Cash Stock Expense	0	16,578,000	16,875,000	'	'	'	'	'	'
Noncontrolling Interest, Description	'	'	'	'	'	'	'the Board of Directors of the Company shall nominate a designee named by LFB Group for election at each annual meeting of the stockholders until such time as LFB Group owns less than 10% of the outstanding Company Common Stock.	'	'
Potential Future Milestone Payments	182,500,000	'	'	'	'	'	'	2,000,000	'
Upfront Fee Received From Sub License	'	2,000,000	'	'	'	'	'	2,000,000	'
Potential Additional Amount Payable On Achievement Of Pre Specified Milestones	'	'	'	'	'	'	'	182,500,000	'
Conversion of Stock, Shares Converted	'	'	'	'	'	7,500,000	'	'	'
Conversion of Stock, Shares Issued	'	'	'	'	'	5,000,000	'	'	'
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,777,962	'	2,777,962	1,545,396	1,232,381	2,500,000	'	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights	2.25	'	2.25	2.25	2.25	0.001	'	'	'
Incremental Common Share Attributable To Security Exchange Agreement	'	'	'	'	'	$750,000	'	'	'

JOINT_VENTURE_Details_Textual

JOINT VENTURE (Details Textual) (USD $)	1 Months Ended		12 Months Ended
	Apr. 19, 2011	Dec. 31, 2011	Dec. 31, 2011
			Thornton Ross Ltd [Member]
Schedule of Equity Method Investments [Line Items]	'	'	'
Equity Method Investment, Ownership Percentage	15.00%	13.00%	'
Loss Contingency, Damages Sought, Value	$7,000,000	'	$20,000,000

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Details Textual) (USD $)

1 Months Ended

12 Months Ended

25 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Jul. 18, 2013

Feb. 24, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2011

Apr. 19, 2011

Aug. 31, 2012

Apr. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 30, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 30, 2011

Dec. 30, 2011

Opus [Member]

National Holdings [Member]

Research Development Expenses [Member]

Research Development Expenses [Member]

Two Thousand Twelve Issuance [Member]

Lfb Group [Member]

Lfb Group [Member]

Private Placement [Member]

Series Preferred Stock [Member]

Two Thousand Twelve Issuance [Member]

Two Thousand Eleven Issuance [Member]

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

5,700,000

695,428

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

Other research and development

'

'

$12,621,161

$3,994,182

$16,645,626

'

'

'

'

'

'

'

$6,267,000

$1,447,000

'

'

Accounts Payable

'

'

'

'

'

'

'

'

'

'

'

'

1,745,000

56,000

'

'

Equity Method Investment, Ownership Percentage

'

'

'

'

'

13.00%

15.00%

'

5.00%

'

'

'

'

'

'

'

Agent Cash Commission Percentage On Proceeds From Shares Issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

Agent Warrant Percentage On Issuance Of Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

WarrantTerm

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

Agent Non Accountable Expense Percentage On Gross Proceeds From Share Issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.00%

Legal Expenses Reimbursed To Agent

'

'

'

'

'

'

'

'

'

'

'

80,000

'

'

'

'

Advisory Fees Expenses Private Placement

'

'

'

'

'

'

'

'

'

'

'

150,000

'

'

'

'

Advance Payments For Research And Development

'

'

'

'

'

'

'

'

'

'

'

'

1,629,340

1,719,828

'

'

Non Cash Compensation Expenses

'

'

'

'

'

'

'

'

'

$437,000

$134,000

'

'

'

'

'